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Abstract 
 
     Lead exposure can cause multiple systemic toxicities, particularly affecting the 
hematopoietic, nervous and renal systems. However, its effects on the thyroid functions 
are not well elucidated and the published studies are controversial. In addition, although 
there are several experimental thyroid models, each one of them has its own limitations. 
Accordingly, in this dissertation, we investigated the possible relationship between lead 
exposure, thyroid functions and short-term systemic toxicity in two animal models, 
namely normal (non-diabetic) and diabetic animals. We also investigated the possibility 
of developing a hormonal thyroid model.  
     In the non-diabetic model, Wistar rats were divided into five groups and treated for 
five days. The four treatment groups received 1, 25, 50, or 100 mg/ kg of lead acetate 
trihydrate intraperitoneally (i.p.), respectively. The control group received i.p. injections 
of distilled water. In the diabetic model, diabetes was induced with an i.p. injection of 60 
mg/ kg streptozocin (STZ). Six weeks later, lead exposure experiments started. Here, 
four groups were studied: a control; and 25, 50 and 100 mg/ kg lead acetate groups. In 
each model, the measured blood lead levels correlated very well with the administered 
doses of lead acetate. Treatment of the animals with lead acetate resulted in significant 
weight loss in both models. Lead exposure caused a dose-related increase in thyroid 
stimulating hormone (TSH) in non-diabetic and diabetic animals. Although, thyroxine 
(T4) and triiodothyronine (T3) levels remained within normal range in non-diabetic 
animals, their levels were reduced in diabetic animals. The highest dose of lead (100 mg/ 
kg) significantly increased white blood cell counts and caused a significant decrease in 
the number of platelets in non-diabetic animals. In addition, C-reactive protein levels 
vii 
 
increased significantly in response to lead exposure in this model. Moreover, there was a 
significant increase in lactate dehydrogenase (LDH), aspartate aminotransferase, total 
bilirubin, and urea levels; following lead exposure in non-diabetic animals. In 
comparison, lead exposure in diabetic animals increased urea levels and caused a 
significant decrease in creatinine levels in plasma. While the concentrations of 
malondialdehyde were not affected, glutathione stores were depleted in response to lead 
exposure in the diabetic animals.  
     In the last stage, we tried to develop a new experimental thyroid model, based on the 
use of hormones. In this experiment, animals were treated for five days with either 
thyrotropin-releasing hormone (TRH) or octreotide (OCT) to induce hyperthyroidism or 
hypothyroidism, respectively. Although there were no effects on T4 and T3 levels, TRH 
was effective in causing an increase in TSH levels. However, TRH also elevated LDH 
levels. The use of TRH did not cause any other side effects on the tested parameters, 
which included weight change, oxidative stress markers and renal and hepatic functions. 
In comparison, OCT failed to affect TSH, T4 and T3 levels, at the dose and treatment 
duration that we used.  
     In conclusion, short-term lead exposure in healthy and diabetic animal models 
affected the functions of the anterior pituitary and thyroid glands, caused oxidative 
stress, liver and kidneys toxicity and induced systemic inflammation. In addition, we 
found that TRH has a potential to induce hyperthyroidism in experimental animals. 
 
 
Keywords: lead, rat, diabetes, thyroid, experimental model and systemic toxicity. 
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 )cibarA ni( tcartsbA dna eltiT
 
 مرض حالة في الذرقية والغذد للرصاص التعرض بين العلاقة عن تجريبي مختبري بحث
   السكري
 
 صالملخ
 
 رأصٞشاد ٕزا ٗٝشَو اىغغٌ، أّظَخ ٍخزيف فٜ عَٞخ أػشاػب ٝغجت ىيشطبص اىزؼشع أُ ػيَٞب اىضبثذ ٍِ إّٔ     
 ىٞغذ اىذسقٞخ اىغذح ٗظبئف ػيٚ آصبسٓ فئُ رىل ٍِ ٗثبىشغٌ ٗاىنيٚ، ٗاىؼظجٜ اىذٍ٘ٛ اىغٖبص ػيٚ اىشطبص
 ٍِ اىؼذٝذ ٗع٘د ٍِ اىشغٌ ٗػيٚ رىل إىٚ ٗثبلإػبفخ ىيغذه، ٍضٞشح حبىٞب اىَْش٘سح ٗاىذساعبد عيٜ، ثشنو ٗاػحخ
 ثٔ، اىخبطخ ٍغبٗئٔ ىٔ اىَْبرط ٕزٓ ٍِ ٗاحذ مو أُ إلا اىَخزجشاد، حٞ٘اّبد فٜ اىذسقٞخ ىيغذح اىزغشٝجٞخ اىَْبرط
 اعٖضح ثبقٜ ٗ اىذسقٞخ اىغذح ٗٗظبئف ىيشطبص اىزؼشع ثِٞ اىَحزَيخ اىؼلاقخ ّذسط ىجحشا ٕزا فٜ فئّْب ٗىزىل
 رط٘ٝش ثَحبٗىخ قَْب أّْب مَب اىغنشٛ، ثذاء اىَظبثخ ٗاىحٞ٘اّبد اىغيَٞخ اىحٞ٘اّبد فٜ اىقظٞش اىَذٙ ػيٚ اىغغٌ
 .اىٖشٍّ٘بد اعزخذاً ػيٚ ٝؼزَذفٜ اىحٞ٘اّبد  اىذسقٞخ ىغذحَشبمو اى عذٝذ َّ٘رط
 ٗاعزغشقذ ٍغَ٘ػبد خَظ إىٚ اىغيَٞخ اىحٞ٘اّبد ّ٘رط فٜ" ٗٝغزبس" فظٞيخ ٍِ  اىزغبسة فئشاُ رقغٌٞ رٌ ىقذ     
 اىز٘اىٜ، ػيٚ ،اىشطبص ٍِ مغٌ/ ٍيغ 001 أٗ 05 ،52 ،1 الأسثؼخ اىؼلاط ٍغَ٘ػبد ريقذ حٞش أٝبً، 5 اىزغبسة
 رٌ فقذ اىغنشٛ ٍشع ىَْ٘رط ثبىْغجخ أٍب اىَقطش، ثبىَبء اىزحنٌ ٍغَ٘ػخ حقِ رٌ ثَْٞب اىجطِ، فٜ حقِ شنو ػيٚ
 ثذأد أعبثٞغ عزخ ٗثؼذ اىجطِ، فٜ  )ZTS(  nicozotpertsٍشمت ٍِ مغ/ ٍيغ 00 ٍقذاسٕب ثغشػخ اىغشراُ حقِ
 ٗ 05 ٗ 52 ٗ اىزحنٌ ٍغَ٘ػخ ٕٜٗ ٍغَ٘ػبد أسثغ دساعخ رَذ رطَ٘اىْ ٕزا ٗفٜ ىيشطبص، اىزؼشع رغبسة
 اىذً فٜ اىشطبص ٍغز٘ٝبد أُ اىَْ٘رعِٞ ملا فٜ اىجحش ّزبئظ اٗػحذ ٗىقذ ،اىشطبص ٍِ مغٌ/  ٍيغٌ 001
 ٍيح٘ظب ّقظب أحذس ىيشطبص اىزؼشع أُ مَب ىيغشراُ، اػطٞذ اىزٜ اىشطبص عشػبد ٍغ ٍجبشش ثشنو رزْبعت
 ٗػيٚ ثبىغنشٛ، ٗاىَظبثخ اىغيَٞخ اىحٞ٘اّبد فٜ )HST( ٕشٍُ٘ ٍغز٘ٙ فٜ ؽشدٝخ ٗصٝبدح اىحٞ٘اّبد ٗصُ فٜ
 فٜ اىطجٞؼٜ اىَؼذه ػَِ ظيذ )3T( صٞشِّٗٞ اٝ٘دٗ صلاصٜ ٗ )4T( اىذسقٞخ اىغذح ٕشٍُ٘ ٍغز٘ٝبد أُ ٍِ ىشغٌا
 أػيٚ اعزخذاً عجت ٗىقذ ثبىغنشٛ، اىَظبثخ اىغشراُ فٜ ّقض قذ اىٖشٍّ٘بد ٕزٓ ٍغز٘ٙ أُ إلا اىغيَٞخ، اىحٞ٘اّبد
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 أّٖب مَب اىجٞؼبء، اىذً خلاٝب ػذد فٜ مجٞشح صٝبدح اىغيَٞخ اىحٞ٘اّبد ّ٘رط فٜ) ميغ/  ٍيغ 001( اىشطبص ٍِ عشػخ
 فٜ صٝبدح ىيشطبص اىزؼشع عجت فيقذ رىل إىٚ ٗثبلإػبفخ اىذٍ٘ٝخ، اىظفبئح ػذد فٜ مجٞشا اّخفبػب عججذ
 ٍغز٘ٙ فٜ مجٞشح صٝبدح ْٕبك مبُ رىل ػيٚ ٗػلاٗح اىحٞ٘اّبد، ٕزٓ فٜ )nietorp evitcaer-C( ثشٗرِٞ ٍغز٘ٝبد
 اىزؼشع ثؼذ ٗاىٞ٘سٝب اىذً طفبسٗ  )esarefsnartonima etatrapsa(ٗ )esanegordyhed etatcal( اّضَٝبد
 اىٞ٘سٝب ٍغز٘ٙ فٜ صٝبدح ثبىغنشٛ اىَظبثخ اىغشراُ فٜ ىيشطبص اىزؼشع عجت أخشٙ ّبحٞخ ٍِٗ ىيشطبص،
 رزأصش ىٌ )edyhedlaidnolam( ٍبدح ٍغز٘ٙ أُ ٍِ اىشغٌ ٗػيٚ اىذً، فٜ اىنشٝبرِْٞٞ ٍبدح ٍغز٘ٙ فٜ ّٗقظب
  .ٍيح٘ظ ثشنو اّخفغ قذ )enoihtatulg( اىغي٘ربصُٞ٘ ٍبدح ٍخضُٗ أُ إلا ىيشطبص ثبىزؼشع
 ٕزا ٗٝغزْذ اىحٞ٘اّبد، فٜ اىذسقٞخ ىيغذح عذٝذ رغشٝجٜ َّ٘رط رط٘ٝش حبٗىْب اىجحش ٍِ الأخٞشح اىَشحيخ ٗفٜ          
 اىحٞ٘اّبد ٍِ الأٗىٚ اىَغَ٘ػخ إػطبء رٌ ظذداى ٕزا ٗفٜ أٝبً، خَغخ ىَذح اىٖشٍّ٘بد اعزخذاً ػيٚ اىَْ٘رط
 ىزحجٞؾ )TCO( اٗمزشٝ٘رٞذ ٕشٍُ٘ اىضبّٞخ اىَغَ٘ػخ إػطبء رٌ ثَْٞب  اىذسقٞخ، اىغذح ّشبؽ ىزحفٞض )HRT( ٕشٍُ٘
 فؼبلا )HRT( ٕشٍُ٘ مبُ ،)3T(ٗ )4T( ٕشٍّ٘بد ٍغز٘ٙ ػيٚ رأصٞشٓ ػذً ٍِ اىشغٌ ٗػيٚ اىذسقٞخ، اىغذح ّشبؽ
 فٜ اسرفبع أٝؼب ػْٔ ّزظ )HRT( ٕشٍُ٘ اعزؼَبه أُ إلا، )HST(ٕشٍُ٘  ٍغز٘ٝبد فٜ صٝبدح إحذاس فٜ
 ٗػلاٍبد اىحٞ٘اّبد ٗصُ ػيٚ أخشٙ عبّجٞخ آصبس أٛ )HRT( ٕشٍُ٘ اعزخذاً ٝغجت ىٌ، ٗ)HDL(اّضٌٝ  ٍغز٘ٝبد
 فٜ أٝبً خغَخ ىَذح اىَؼطبح اىغشػخ حغت )TCO( ٕشٍُ٘ ٝغزطغ ىٌ اىَقبثو ٗفٜ ٗاىنجذ، اىنيٚ ٗٗظبئف الأمغذح
 . )3T(ٗ  )4T(ٗ )HST( ٍغز٘ٝبد ػيٚ رأصٞش أٛ اسذاح
 ٝؤصش اىغنشٛ ثذاء ٗاىَظبثخ اىغيَٞخ اىحٞ٘اّبد فٜ اىقظٞش اىَذٙ ػيٚ ىيشطبص اىزؼشع ثأُ ٕزا ٍِ ّٗغزْزظ     
 قذ أّٔ مَب ،ٗاىنيٚ اىنجذ فٜ رغََب ٗٝغجت الأمغذح، ٗػلاٍبد اىذسقٞخ ٗاىغذح الأٍبٍٞخ اىْخبٍٞخ اىغذح ٗظبئف ػيٚ
 ّشبؽ فٜ صٝبدح احذاس ػيٚ اىَقذسح )HRT( ىٖشٍُ٘ فئُ رىل، إىٚ ٗثبلإػبفخ اىغغٌ، فٜ ػبٍخ اىزٖبثبد ٝغجت
           .اىزغبسة حٞ٘اّبد فٜ اىذسقٞخ اىغذح
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Chapter 1: Introduction 
      
1.1. General Overview of Lead Exposure and Toxicity 
     As an element that has been used widely throughout history and until today, lead has 
proven itself as a useful heavy metal and as a toxin [1]. Consequently, it became one of 
the most commonly studied heavy metals [2, 3]. The latter are broadly defined as those 
that have a potential to cause toxicity and adverse effects either to humans or the 
environment [4]. Unlike some other metals such as zinc and manganese which are 
required as essential nutrients, lead has no known beneficial human physiologic 
function [5]. In addition, it can neither biodegrade i.e. it cannot break down, nor can it 
be detoxified by living organisms [6, 7]. Two types of lead are known, namely, organic 
and inorganic. Organic lead is much more toxic, particularly to the nervous system, than 
the inorganic type [8]. It‟s worth mentioning that the majority of poisoning cases with 
lead are caused by inorganic lead [9]. Examples of inorganic lead are lead carbonate, 
lead chromate, lead monoxide, lead tetraoxide and lead acetate [8]. According to the 
U.S. Centers for Disease Control and Prevention (CDC), lead is the main environmental 
toxin in children [1] and as such it results in one of „the most prevalent diseases of 
environmental origin among children‟ [10]. Lead ranks second on the priority list of 
hazardous substances published by the U.S. Agency for Toxic Substances and Disease 
Registry (ATSDR) [11]. This list includes several chemicals e.g. lead, arsenic, benzene 
and cadmium. These chemicals are labeled as hazardous substances and were added to 
the list because of their “frequency, toxicity and potential for human exposure at 
National Priorities List (NPL)” [11].     
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1.1.1. Exposure among the General Population 
     Lead is ubiquitous in the environment [12]. The main route of exposure in the 
general population is ingestion [8, 13]. According to World Health Organization 
(WHO), over 80 % of the oral intake of lead is through food, dirt, and dust [8].  Other 
sources of lead exposure are lead-based paints especially in children; consumption of 
contaminated food, fish kidney and liver, drinking polluted water running in old lead 
pipes, or soldered joints [8, 14]. On a regional level, data from Saudi Arabia showed 
that „vegetables‟ and „cereals and cereal products‟ are the major dietary sources for lead 
exposure; as each one of these two groups represent about 25 % of the total dietary 
consumption [15]. In comparison, in a recent study in 15 European countries, a total of 
140,000 results of measurable lead levels were found in food and tap water samples 
[16]. In Mexican immigrants in the U.S., tamarind and chili powder are known sources 
of lead exposure [17]. Besides food and water, another important source of lead 
exposure is the use of traditional remedies e.g. „Bint Al-dhahab khol or Indian surma‟, 
which is particularly common in Middle Eastern countries e.g. Oman and UAE [17-23]. 
In a study conducted in Belgium, traditional teapots were found to be contaminated with 
different metals including lead, which can leach and thus might result in lead poisoning 
[24]. A recent study carried out in Saudi Arabia demonstrated that lead-paints are still 
being manufactured locally with lead levels reaching as high as 755 ppm, which 
exceeds the U.S. Environmental Protection Agency‟s (EPA) permissible value of 600 
ppm [25].  
     In the U.S., lead is considered one of the main constituents of Criteria Air Pollutants 
(CAP). These represent contaminants in the ambient air that have a potential to cause 
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adverse health effects to the general public. Thus, the levels of CAPs are regulated, 
monitored and should not exceed the limits set by federal agencies such as EPA and 
local states [26, 27].  
 
1.1.2. Occupational Lead Exposures  
     In the past, the use of leaded gasoline in automobiles, which was composed of 
organic lead compounds such as tetraethyl and tetramethyl lead [28], was a major cause 
for environmental lead exposures. These compounds were used in order to improve the 
performance of automobile engines [8]. This practice has been phased out in many 
countries since the 1970s [28], although around 9 countries are still using leaded 
gasoline [8]. In Korea, the initiatives to phase out leaded gasoline started in 1986 and by 
the year 2000 there was a tremendous reduction in lead levels [14].  Oman started using 
unleaded gasoline in October 2001 [29]. In comparison, the UAE started to use 
unleaded gasoline in 2003 [30]. This involved major changes such as converting 500 
filling stations to unleaded gasoline, training of staff, and conducting educational and 
awareness programs throughout the country [30].  
     Examples of occupational sources of lead exposure are car batteries‟ manufacturing, 
radiator repair shops, welding and cutting operations, solid waste burning, and 
construction [28, 31]. There has been a continuous increase in lead‟s utilization in 
storage batteries and electronics; particularly in Asia [26]. The vast majority (about 
97%) of batteries worldwide are recycled, often in underdeveloped countries [8]. At 
present, 70% of lead is used in storage batteries [3, 32], where the metal grids are made 
up of lead and the paste in the batteries is lead oxide [28]. As an example of 
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occupational exposures in the Arabian Peninsula, 12 % of a total group of 89 
servicemen and 69 public transport drivers in Saudi Arabia had BLL of more than 
40µg/ dL [33].  
     Occupational exposures typically take place through inhalation of lead oxide [8, 32]. 
In addition, they are often chronic in nature and might result in more serious 
consequences. One of the major problems with occupational exposures in general is the 
limitation of adequate surveillance systems for injuries and diseases, despite the fact 
that at present various work-related diseases cause more than 5000 deaths everyday 
worldwide [34]. 
 
1.1.3. Exposure Cut Levels  
     Health organizations such as CDC have continuously and progressively decreased 
the minimal action values for BLL. In the past, the BLL action level in children was set 
at 10 µg/ dL. In 2012, a new „reference level‟ of 5 µg/ dL was established [35]. The 
corresponding level in occupational exposures should not exceed 25 µg/ dL [36]; 
however, by now, it is clear that no lower threshold for BLL could be established [37]. 
Perhaps, that is why no safety level for lead exposure has been established so far [14]. A 
study conducted in 2006 showed that BLL even below 10 µg/ dL in adults are 
associated with cardiovascular fatality [38].  
     Since lead-based paints are a major cause of lead exposure, particularly in children, 
the USA banned the use of lead in paints in 1977. Accordingly, lead levels in paint 
should not exceed 0.07 mg/ cm² [17]. Despite such strict regulations, around 40 million 
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houses in the USA were estimated to have lead-related problems in the year 2000 [17]. 
The majority of these houses are probably built before 1950. 
 
1.2. Lead’s Toxicokinetics 
1.2.1. Absorption 
     The extent of inorganic lead absorption by the gastrointestinal tract (GIT) is 
mediated by several factors such as the physiological state of a person and the particular 
compound being ingested [13]. In comparison to larger pieces e.g. paint chips, lead 
particles that are smaller in size such as those in dust are more completely absorbed [2, 
3, 9]. Other factors that facilitate the GIT absorption of lead are poor caloric intake, the 
consumption of diets rich in fats [2], and fasting conditions [2, 39]. In addition, there is 
more absorption of lead when it is dissolved in water than when it is attached to food or 
solid matter e.g. soil [13, 40]. Consequently, lead oxide, a very soluble compound that 
is utilized in battery manufacturing plants, can be easily absorbed [41]. 
     There are three transporters involved in the GIT absorption of lead. The first one is 
the active process mediated by the calcium transporter [2]. Lead also competes for 
absorption as well as for binding to the „mobilferrin‟ protein [12], which usually 
transports ferric iron (Fe
3+
) [42]. Competition with the divalent metal transporter 
(DMT), required for the transportation of ferrous iron (Fe
2+
) [42], is the third postulated 
mechanism for its absorption [43]. There is an inverse relationship between vitamin D 
intake, iron and calcium stores in the body and lead absorption in the GIT [44]. 
Consequently, dietary deficiencies of these minerals e.g. iron or calcium enhance lead‟s 
absorption [9, 43].  
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     In contrast to ingestion, 95% of inhaled inorganic lead is absorbed [13, 45, 46]. 
Factors favoring the absorption of inhaled lead include smaller particle size, higher 
concentrations [47], and increased respiratory rate e.g. in children and in physically 
very active workers [12]. On the other hand, dermal absorption of organic lead, which is 
often encountered in occupational settings, is also possible. For instance, tetraethyl lead 
can be easily absorbed through the skin [8, 13, 40, 48]. Furthermore, both types of lead 
and particularly the organic type can cross the placenta and their ultimate levels in the 
fetus are positively associated with maternal BLL [48]. Lead is also found in milk and 
can pass from lactating mothers to their babies [49].  
 
1.2.2. Distribution 
     In the blood stream, the vast majority of lead (99%) is bound to hemoglobin in the 
RBCs, so only 1% circulates in plasma. This is the amount available for eventual 
distribution to various soft tissues [43, 47, 48]. Although transferrin is responsible about 
the transportation of ferric iron, its C2 variant might also have a role in lead poisoning 
[14]. Lead has a decreasing affinity for the following organs: liver, kidneys, lungs and 
brain. Characteristically, the penetration rate of lead into the CNS is higher in children 
than in adults [48]. In the 3 compartment model, which are blood, soft tissues and bone, 
lead mainly targets the second compartment i.e. soft tissues [2, 12]. 
     Ultimately, 94% of absorbed lead in an adult is stored in bones and teeth; in 
comparison to around 73% in children [13, 45]. Although it gets deposited in both, lead 
has a higher preference for bones than for teeth. In calcium deficiency states, more lead 
is absorbed and fixed into the bones [48], where it is found as tertiary lead phosphate. 
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This is why diets rich in phosphate encourage the storage of lead in bones [43]. After 
deposition in bones, lead is thought to be relatively inert [12, 48].  
     The half-life (t½) of inorganic lead in blood is relatively very short, only about 30 
days, whereas, in bones, its t½ is 27 years [2]. Over time, lead is mobilized and is 
slowly released back into the circulation. Any stress on bones e.g. fractures, infections, 
menopause, osteoporosis or even pregnancy and lactation can release lead from bones 
and may cause toxic effects; even in the absence of recent exposures [2, 3, 40, 47, 48]. 
Because of this mobility, up to 50 % of lead in the blood might represent endogenous 
release from bones [12, 47]. 
 
1.2.3. Metabolism 
     Organic lead e.g. tetraethyl lead, which is a lipid soluble compound, was added to 
petroleum in many countries in the past. After exposure e.g. sniffing by adolescents, 
this compound is metabolized in the liver and converted into another organic substance 
called triethyl lead, thereby exerting its toxic effects. In addition, organic lead can also 
get converted into the inorganic form [12, 48], which in living organisms cannot be 
metabolized any further [26].  
 
1.2.4. Elimination 
     Regardless of the route of exposure, eventually lead is mainly excreted in either 
urine or bile [13]. Renal excretion is by glomerular filtration where lead appears in the 
urine unchanged [47, 48]. Interestingly, the half-life (t½) of renal excretion of lead is 
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dependent upon and very comparable to where lead is e.g. renal excretion t½ is 25 days 
for blood lead, in contrast to being about 25 years for lead in bones [48].  
     Since only about 1% of blood lead is available for renal filtration (because the rest is 
bound to RBCs), chronic lead toxicity can develop fast if a subject‟s total exposure and 
intake of lead is increased even if only by a small amount [43]. Besides renal excretion, 
about a third of absorbed lead is excreted in bile [12, 47]. In comparison to adults, 
children have a lower lead excretion rate [12]. Lead can also be eliminated through milk 
[12] and sweat; and lead deposits can be found in hair and nails [39, 43].    
 
1.3. Lead’s Toxic Effects 
     Lead causes multiple systemic toxicities; and the organs that are most vulnerable to 
lead deposition are the nervous system, kidneys and liver [49, 50]. Lead exposure and 
hence its toxicity can be either acute or chronic in nature. In the initial stages and at 
minimal levels of exposure, clinical presentation is extremely vague and nonspecific 
and can easily pass unrecognized [2]. More specific and systemic features become 
evident at higher levels of exposure and cause renal failure and encephalopathy. In the 
coming sections, and in addition to systemic toxicity, specific effects related to children, 
the elderly and people with chronic diseases such as diabetes and hypertension will be 
highlighted and discussed in more detail.  
 
1.3.1. Hematologic Effects 
     Effects on the hemopoietic system are a sensitive indicator of the toxic effects of 
lead [47]. It is well known that lead exposure can result in anemia [51, 52]. In 
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developing countries, another common problem is iron deficiency [53]. Shah et al. 
provided a list of several studies that showed an association between lead exposure and 
iron deficiency [53]. As such, these two conditions i.e. lead exposure and iron 
deficiency are interrelated and can eventually cause and worsen existing anemias [53].  
     There are several mechanisms that are involved in lead-induced anemia, the most 
important of which are the following. The first mechanism is lead‟s competition for 
binding to the proteins that are required for the GIT transportation of iron, which is an 
essential component for heme synthesis. The second mechanism is related to lead‟s 
ability to form covalent bonds with sulfhydryl groups; particularly those that are present 
in metalloenzymes such as delta-aminolevulinic acid dehydratase, coproporphyrinogen 
oxidase and ferrochelatase  [2, 43, 48]. Related to heme, which is a cornerstone in the 
structure of hemoglobin, myoglobin, cytochromes and catalases [43]; five out of the 
seven enzymes that are involved in its biosynthesis are inhibited by lead [54] as shown 
in (Figure 1). The suppression of both δ- aminolevulinic acid dehydratase (ALAD) and 
ferrochelatase represents the most important inhibitory effects of lead on the 
hemopoietic system [43, 47, 54, 55]. Ferrochelatase enzyme is also referred to as heme 
synthetase in some resources [54].      
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Figure 1: Mechanism of lead toxicity on heme biosynthesis [56]. 
 
     Because of these inhibitory effects, instead of having heme, circulating red blood 
cells (RBCs) have protoporphyrin IX [43]. These RBCs get chelated by zinc at the site 
of iron [43, 47, 55]. This results in the formation of zincprotoporphyrin, which 
fluoresces, therefore; it is used as a diagnostic test for lead toxicity. Besides 
zincprotoporphyrin, the inhibition of the previously described enzymes causes an 
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elevation in the urinary levels of porphyrins, coproporphyrins and δ-aminolevulinic acid 
(dALA) [43, 47, 55, 57]. In addition, reduced heme concentration exerts a negative 
feedback effect and stimulates the synthesis of dALA, thereby leading to further 
increases in dALA levels [55] (Figure 1). 
     Apart from decreasing iron absorption and inhibiting heme˗synthesis enzymes [53], 
lead-induced anemia might also result from splenic sequestration and the phagocytosis 
of RBCs, which were shown to be accompanied by an increase in the weight of spleen 
in lead-exposed rats [51]. In addition, lead exposure tends to shorten the lifespan of 
RBCs; mainly through increasing their membranes‟ instability and fragility [55]. The 
ultimate anemia, caused by all of the previously described mechanisms, is very similar 
to iron-deficiency anemia i.e. being microcytic and hypochromic [43, 47, 54]. This late 
manifestation of lead poisoning [41] is particularly important in those subjects who 
already had iron deficiency anemia before any lead exposures; since after such 
exposures, the anemia can obviously get worse. Besides causing anemia and a reduction 
in RBC levels [58], chronic lead exposure also decreases hematocrit counts [51, 59]. 
     In addition, the breakdown of the remnants of ribonucleic acid (RNA) by 
pyrimidine-5-nucleotidase is inhibited by lead. This results in the basophilic stippling of 
RBCs due to the accumulation of RNA aggregates [12]. Although a very characteristic 
feature, basophilic stippling is not pathognomonic of lead toxicity [43].  
 
1.3.2. CNS Effects 
     In medical literature, a lot of emphasis has been placed on the toxic effects of lead 
exposure on the nervous system, where interference with the metabolism of divalent 
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cations e.g. calcium and zinc [55, 60] underlies the basis of lead‟s toxic effects. Lead 
has a „higher affinity than calcium to the calcium-binding protein calmodulin‟ [61]. 
Suppression of calmodulin, pyruvate kinase and other enzymes in the CNS affect the 
functioning and disturbs the homeostasis of several neurotransmitters e.g. 
glutamatergic, dopaminergic and cholinergic systems [2, 47, 55, 57, 62]. In addition, 
acute lead exposures have been shown to increase brain catalase (CAT) levels [63-65].   
     Lead exposure is a well-known cause for cerebral edema. A previous study 
demonstrated that there was a difference in the various regions of the brain that became 
edematous and this depended on the particular doses of lead acetate that were 
administered to rats, where, in comparison to cerebral cortex, the cerebellum was more 
sensitive to develop lead-induced edema [66]. In this regard, several mechanisms have 
been postulated to be the cause for blood brain barrier (BBB) disruption. Lead was 
reported to stimulate the „vascular endothelial growth factor/vascular permeability 
factor in cultured astrocytes‟ and to cause cerebellar vasogenic edema and hemorrhage 
[67]. „Occludin‟ is one of the important proteins that make up the tight junctions of 
BBB [68]. Lead exposure in experimental studies has been shown to cause a reduction 
in the level of this protein (down-regulation) [69] as well as in the level of the 
cytoplasmic protein ZO-1 [68], and consequently resulted in increasing the permeability 
of the BBB. Lead also disrupts the normal functioning of cerebral capillaries by 
inducing protein kinase C, which is a calcium-dependent enzyme that phosphorylates 
many proteins [3, 55]. With increased permeability, albumin, ions, and water enter the 
cerebrospinal fluid (CSF), causing edema in the surrounding areas [57]. Consequently, 
the increase in intracranial pressure results in the death of neurons and the proliferation 
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of glial cells [47, 54, 55, 57]. In contrast to adults, the incompletely developed BBB in 
children is much more vulnerable to the toxic effects of lead exposure [70]. This could 
be due to lead‟s effect on claudin-1, which is one of the important cellular proteins that 
are needed for the integrity of the tight junctions [71]. Lead was also shown to cause a 
reduction in mRNA and protein levels of claudin-1, thereby increasing BBB‟s 
permeability [71].   
     Synaptic plasticity refers to the strength of connections between two neurons [72].  
By inhibiting the expression of the N-methyl D-aspartate receptor (NMDAR) in the 
hippocampus, lead impairs long term potentiation and de-potentiation [69] and thus 
affects synaptic plasticity and results in impairments in learning abilities and memory 
[70]. On the other hand, there are various psycho-neurological diseases that are either 
well-confirmed or at least associated with lead exposure. Lead encephalopathy is one of 
the most serious complications of lead toxicity, of which several pediatric cases have 
been reported in Oman [19, 73, 74]. In 2011, autism in 25 Saudi children was found to 
be associated with having high blood lead levels [75]. Recently, it has been shown that 
chronic lead exposure carries an increased risk of two-fold for the development of 
Parkinson‟s disease [76]. Besides, epigenetic studies showed that exposure to lead in 
early life caused an increase in protein and mRNA levels of tau, thus leading to an 
increase in tau phosphorylation in older mice [77]. This might eventually result in 
developing Alzheimer‟s disease [14].  
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1.3.3. Renal Effects 
     In the kidneys, the main site of action of lead is in the proximal tubules [54, 55], 
where one of the most characteristic features of lead exposure is revealed. This is the 
appearance of inclusion bodies, which are an inert form of lead and protein complexes 
[12] in the nuclei of renal cells [43, 47, 54, 55]. Metallothionein has been demonstrated 
on the outer layer of inclusion bodies, which suggests its protective role and 
involvement in their formation [47, 78-80]. Metallothioneins have low molecular weight 
and are dense with cysteine residues and thiol groups [14]. Among their many 
functions, metallothioneins have a major role in the various steps of absorption, 
transportation, and elimination of metals leading eventually to the detoxification of 
several metals including lead and mercury [14].     
     One of the most important tests for the diagnosis of renal functions and its failure is 
the glomerular filtration rate (GFR), which is an early indicator of renal injury [81]. 
Exposure to lead in early life can impair the growth of glomeruli, leading at the end to 
renal malformation and hypertension [81] i.e. the exposure to low levels of lead is 
considered a risk factor for developing chronic renal disease [82]. In such cases, GFR 
becomes a useful tool for assessing renal function. Additional manifestations of lead 
toxicity include the elevation in urea and creatinine levels [83]. Besides, terminal 
deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining is 
frequently used to look for apoptosis, which is defined as programmed cell death. Such 
studies have demonstrated that there is a significant increase in TUNEL-positive cells in 
lead exposed animals i.e. lead exposure is a cause of cellular death [83].  
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     Lead exposure has two additional effects on the kidneys. Under normal 
physiological conditions, 25-vitamin D is converted into 1, 25-vitamin D through the 
action of a hydroxylase enzyme, which is a target for inhibition by lead [2]. Thus, 
leading to a reduction in the generation of the active form of vitamin D. Lead is also 
associated with a higher rate of hyperuricemia and gouty attacks [12, 43, 47].  
  
1.3.4. Cardiovascular Effects 
     Related to the cardiovascular system (CVS), numerous studies showed a positive 
relationship between lead exposure and hypertension [84]. Systolic as well as mean 
blood pressure were found to be higher in occupationally lead-exposed workers, in 
comparison to a control group [85]. High readings of systolic and mean blood pressure 
were also reported in hypertensive subjects with lead exposure who were compared to 
hypertensive patients with no history of lead exposure [86]. In another study, acute 
exposure to low levels of lead was shown to result in increasing cardiac muscle 
contractility and increasing ventricular systolic pressure, which are among the 
predisposing factors that can lead to the development of hypertension [87]. Additional 
data from experimental animal studies support this relationship as after two months of 
lead exposure, there was an increase in systolic blood pressure in rats [88], whereas, in 
another study there was a positive effect on both systolic and diastolic arterial pressure 
as well as on cardiac contractility [89]. Furthermore, lead exposure even during fetal 
life and through maternal exposure to lead in drinking water during lactation resulted in 
an increase in systolic blood pressure in rat pups [90].  
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     Lead-induced hypertension and the elevated systolic blood pressure [25, 86] are 
believed to be mediated through several mechanisms. The first is by stimulating the 
renin-angiotensin system, which elevates blood pressure [12] in both adults and children 
[47]. The second important mechanism is mediated through lead‟s effects on the 
vascular smooth muscles, where it inhibits Na+/K+ ATPase and activates Na+/Ca++ 
transporter [12], therefore, increasing the concentration of calcium within cells [3, 57]. 
In addition, lead can increase the levels of endothelin and thromboxane as well as 
changing the elasticity of arteries [47]. Lead can also activate the sympathetic nervous 
system, resulting subsequently in the release of catecholamines [84]. On the other hand, 
lead is also believed to inhibit nitric oxide [12] and cGMP [47], both of which relax 
vascular smooth muscles.  
     In addition, lead exposure widens pulse pressure [91], which represents the 
difference between systolic and diastolic blood pressures and gives an indication about 
the level of stiffness of arteries. High pulse pressure is also a risk factor for left 
ventricular hypertrophy, which is a predisposing factor for hypertension [86] and 
cardiovascular complications [84]. Lead also caused an enhanced responsiveness to 
norepinephrine in animal studies and consequently resulted in more dysrhythmias [12]. 
     The European-developed SCORE system uses several risk factors such as gender, 
age, total cholesterol, systolic blood pressure, and smoking status in order to 
systematically evaluate the risk for developing coronary events. Based on this method, 
lead-exposed workers in Poland were found to have a higher incidence of fatal heart 
events than non-exposed workers [92]. It is also believed that lead can induce the 
development of pro-atherosclerotic changes because of its effects on lipid profile, which 
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include having increases in the levels of total cholesterol, LDL, and triglycerides [84]. It 
is postulated that these abnormalities are caused by several mechanisms such as the 
stimulation of lipid synthesis and lipid peroxidation, and by the alterations in the 
metabolism of polyunsaturated fatty acids [84].  
     Homocysteine is considered „a novel biochemical marker‟ [81] and a risk factor for 
cardiovascular and neurodegenerative diseases [89]. A previous study has shown that 
there is a positive association between lead exposure and homocysteine levels [89]. The 
same study showed that vitamin B6 and folate could minimize homocysteine levels in 
lead-exposed people, thereby exerting a protective effect.  
 
1.3.5. Skeletal Effects 
     As mentioned earlier, the vast majority of lead is eventually deposited in bones; and 
a lesser concentration is stored in teeth. In these tissues, lead can replace calcium, 
resulting in the formation of tertiary lead phosphate. Calcium deficiency promotes the 
storage of lead. The skeletal manifestations are also mediated through lead‟s effects on 
the parathyroid glands, where it interferes with the homeostasis of calcium and vitamin 
D [12, 47]. In the past, it was thought that lead in the bones is inert [12, 48]. However, it 
is now believed that lead exposure, even at „environmentally relevant levels‟ i.e. at 
relatively low exposure levels; can postpone the healing of fractures. Furthermore, 
higher exposure levels were shown to result in fibrous non-unions [93]. Similarly, 
accumulation of lead in the teeth inhibits mineralization and can subsequently lead to an 
increased rate of dental caries [47]. In a clinical case report, lead poisoning (BLL 
125μg/ dL) through the use of old utensils caused chronic pain in both knees and 
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muscular fibrillations [94]. Radiographic tests showed pathognomonic features of 
osteonecrosis (e.g. bone infarction) in the knee joint [94].    
 
1.3.6. Carcinogenicity 
     Lead is considered to be a „facilitative or permissive carcinogen‟ i.e. it has the ability 
to enhance the carcinogenic effects of other agents [95]. In addition, there is conclusive 
evidence from experimental studies that lead is a carcinogen; and at the same time, 
associations from epidemiological studies are growing [96]. Consequently, EPA 
considers inorganic lead a probable human carcinogen (Group B2) [32, 97], whereas, 
the International Agency for Research on Cancer (IARC) has upgraded it from (Group 
2B) to (Group 2A) [98-100].  
     Regarding its mechanisms of action, lead is believed to cause indirect genetic 
damage through DNA fragmentation [101], suppression of the formation and the repair 
of DNA, causing oxidative stress [102], and by interfering with DNA binding proteins 
and tumor-suppressor proteins [96, 103]. Lead can also change the DNA methylation of 
several important molecules e.g. ALAD [14] and cause chromosomal aberrations in 
vitro and in vivo [100]. In addition, the stimulation of protein kinase C increases the 
synthesis of DNA, which can subsequently induce replication and hyperplasia [55]. 
Lead can also cause an acceleration in the growth rate of tumors [104] and it can 
counteract the protective actions of the anticarcinogenic agent selenium, and thus, lead 
has a potential to promote carcinogenicity [105]. 
     The most common sites for lead-induced tumors are the kidneys, brain, lung, and 
prostate [96]. In humans, chronic occupational lead exposures have been associated 
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with renal and pulmonary cancers in epidemiological studies [106]. The assessment of 
more than 4000 lead-exposed workers in printing industry revealed a strong association 
between renal and pancreatic cancers in both genders and inorganic lead exposure 
[107]. Another occupational health study estimated exposure levels to lead dusts and 
fumes and concluded that lead exposure increases the risk for developing meningiomas 
[108]. In another study, patients with ductal breast carcinoma had a significantly higher 
level of lead in blood and hair samples, in comparison to a control group [104]. At the 
same time, lead levels in their hair samples were positively correlated with tumor 
volume, whereas, selenium levels had a negative correlation with tumor volume [104].   
  
1.3.7. Immunological Effects 
     Lead exposure is implicated in causing stimulatory as well as suppressive effects on 
the immune system. For instance, lead can cause an increase in the levels of 
immunoglobulin E (IgE), thus leading to type I hypersensitivity reactions and enhancing 
the likelihood for the development of allergic conditions e.g. asthma [109]. Respiratory 
sensitization and inflammatory changes, similar to asthmatic manifestations, were 
further demonstrated in guinea pigs that were exposed to lead acetate inhalation. These 
animals developed an increase in WBC counts, interleukin (IL)-4, interferon (IFN), 
histamine and IgE levels [110]. In addition, lead exposure was associated with an 
increase in IL-10 levels in occupationally exposed workers, in comparison to a control 
group, perhaps due to having an increase in tumor necrosis factor (TNF)-alpha levels 
[111]. In certain areas of Zambia, soil is contaminated with lead. In-vitro studies in this 
country showed that exposure of cultured WBCs from cattle to lead for 24 hours caused 
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an increase in the expression of mRNA of metallothionein-2 (MT-2), TNF-alpha, IL-1 
beta, IL-6 and inducible nitric oxide synthase (iNOS) [112].  
     On the other hand, in another occupational health study, lead was found to have 
some suppressive effects as it caused a significant reduction in CD3(+), CD4(+)/ 
CD8(+) ratio, IL4, TNF-alpha and IFN-gamma levels, together with having significant 
increases in CD8(+) and IL-10 levels [113]. In another study, CRP levels were 
significantly high, whereas, IgA and IgT levels were low in lead exposed workers [114]. 
In addition, in an in-vitro study, lead was shown to inhibit the phagocytic activity and 
cellular adhesion of peritoneal macrophages, taken from mice [115], again 
demonstrating the depressive nature of lead exposure on the immune system. As such, 
these two studies concluded that lead might eventually weaken the immune response 
[113, 114], and thus increase the vulnerability to develop infectious and inflammatory 
diseases and cancer [114]. 
 
1.3.8. Gastrointestinal Effects 
     Lead poisoning in clinical cases can cause GIT disturbance e.g. nausea, vomiting, 
abdominal pain, and constipation [116]. In an experimental study in rats, there was an 
increase in basal and acetylcholine-stimulated gastric motility; and this was suggested 
to be attributed to an increase in nitric oxide (NO) levels [116]. The same authors also 
showed that NO in low-dose lead-exposed rats decreased gastric acid secretion, 
whereas, high lead-exposure levels increased acid secretion [117]. Oxidative damage is 
often associated with pro-ulcerative factors and is believed to be a predisposing factor 
for gastric ulcers [118]. Examination of the gastric mucosa of rats that have been 
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exposed to lead acetate in drinking water for 15 weeks and then exposed to an oral 
mixture of HCl and ethanol revealed lipid peroxidation, a reduction in catalase, 
superoxide dismutase and nitrite levels [118]. This demonstrates lead‟s ability to 
aggravate the ulcerative effects of HCl and ethanol, possibly through causing oxidative 
stress in the exposed animals [118].       
     Furthermore, lead exposure causes a wide range of abnormalities in the liver. This is 
because the liver is one of the favorite sites for lead‟s deposition, for example, even 
relatively short term exposures in rats for two weeks resulted in lead‟s accumulation in 
the liver [119]. Lead can cause a disruption in the hepatic oxidative parameters e.g. it 
elevates the levels of hepatic transaminases and superoxide dismutase (SOD) [59]. Lead 
also caused significant reductions in two steroid metabolizing enzymes, namely 17-beta 
hydroxysteroid oxidoreductase and uridine diphosphate-glucuronyltransferase, besides 
causing a reduction in hepatic DNA levels [119]. There was also an increase in acid 
phosphate levels in response to lead exposure [58]. A recent study in Wistar rats 
showed that chronic exposure over 4 months to low lead levels (0.06 %) in drinking 
water could initiate fibrogenic changes in the liver [50]. In addition, lead can inhibit the 
synthetic functions of the liver, causing a reduction in total protein and albumin levels 
[58]. Histologically, it causes degenerative and inflammatory changes and portal edema 
in the liver [120]. 
 
1.3.9. Reproductive Effects 
     In July 2003, the European Union (EU) classified lead as a category 1 agent because 
of its toxicity to the reproductive system (embryo-toxic). Based on such classifications, 
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it banned the utilization of lead, mercury, or cadmium in electronic gadgets [26]. Males 
exposed to lead might present with hypospermia and impaired sperm morphology and 
mobility e.g. in a study on 60 males, lead levels were correlated with impaired sperm 
motility, sperm concentration, and DNA damage [121], whereas, in patients with no 
occupational exposure, increased lead levels in semen were associated with reduced 
sperm counts [122]. Another study showed that maternal cord lead levels were 
associated with reduced height and small head circumference in their school-age 
children [123]. 
     In comparison, several experimental studies documented the reproductive toxic 
effects of lead exposure. For example, a previous experimental study in rabbits that 
were exposed to lead in drinking water for 12 weeks showed several reproductive 
abnormalities in the testes and seminiferous tubules e.g. abnormal sperms, degenerative 
changes and necrosis [124]. Diminished spermatogenesis leading to impaired fertility 
was also demonstrated in mice exposed to lead orally over 2 months [125]. In these 
animals, lead deposits were found in the testes [125].  Another study that was conducted 
in mice has shown that maternal lead exposure during lactation resulted in significant 
effects in male pups, which had a reduction in the weight of their testis, low levels of 
serum and testicular testosterone, low numbers of spermatozoa, and reduced expression 
of several important enzymes that are required for the synthesis of testosterone [49]. On 
the other hand, the oral exposure of female rabbits to lead over 8 weeks resulted in 
degenerative changes in the ovarian follicles and apoptotic changes in the endometrial 
lining tissues [101].  
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1.3.10. Lead Exposure and Oxidative Stress 
     Lead exposure is also associated with oxidative damage [126, 127] such as the 
production of ROS and the overconsumption of intracellular glutathione stores [127, 
128], which is one of the main antioxidant defense mechanisms in the human body. A 
related chemical is the glutathione-S-transferase enzyme, which is a phase II enzyme 
that is required for the detoxification process of many agents including heavy metals 
[129]. Lead can inhibit several antioxidant enzymes including glutathione-S-transferase, 
hepatic and brain glutathione reductase, and the selenium-dependent glutathione 
peroxidase enzyme [130, 131]. In comparison, it causes a reduction in the hepatic 
copper-dependent-SOD levels [126]. Lead exposure also caused a reduction in the 
levels of SOD and glutathione peroxidase; and an increase in MDA levels in renal tissue 
homogenates [83].  
     In order to counteract the toxic effects of lead exposure, mice were given milk by 
gavage. Milk was further fortified with the antioxidant bamboo leaves, vitamin C, 
calcium lactate, ferrous sulfate, and zinc sulfate for a total duration of 7 weeks [132]. 
The use of this formula resulted in decreasing BLL, lead‟s distribution to soft tissues 
including liver, kidneys and brain, together with ameliorating lead-induced oxidative 
damage [132]. The effects of oxidative stress will be discussed in more detail in chapter 
4: Diabetic Animal Model.  
 
1.3.11. Effects on Children 
     The two most important causes for lead poisoning in the 20
th
 century were leaded 
gasoline and lead-based paints [8]. As with other subgroups in the general population, 
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children are exposed to lead mainly through ingestion [17]. In addition, parents may 
chronically expose their offspring to low lead levels through their contaminated bodies 
and clothes [12] or through maternal-fetal route in occupationally exposed women as 
lead easily crosses the placenta [17, 45, 46].   
     The effects of lead exposure in children might be different than its effects on adults 
[81]. Children are particularly vulnerable to lead poisoning since they carry several risk 
factors that predispose them to higher levels of toxicity once they are exposed to lead 
[17]. In fact, children‟s GITs absorb around 40 - 50% of ingested lead [12] compared to 
only about 3 - 10% in adults [13]. After absorption, children retain higher amounts of 
lead (about one third), whereas, adults retain less than 5% [47, 48]. Also, children tend 
to deposit more lead in soft tissues, rather than in bones, and their BBB is still 
undergoing development. In addition, the levels of lead exposure become much higher 
if a child is used to pica [8]. Since poverty is associated with malnutrition, poor children 
are often deficient in iron and calcium; and this will ultimately further predispose them 
to the toxic effects of lead exposure [8]. 
     The peak age for lead poisoning in children is between 18 to 30 months of age [17]. 
Low levels of exposure (BLL even below 10 µg/ dL) may ultimately damage various 
organs; even if the initial presentation was asymptomatic [8]. Furthermore, BLL of less 
than 5 µg/ dL can cause brain damage [8]. In addition, gender may play a role in lead 
exposure cases. For instance, in 108 Indonesian children who were 6-7 years old; males 
were found to have significantly higher BLL than females (6.8 ± 2.0 µg/ dL versus 5.9 
± 1.9 µg/ dL) [133]. This was attributed possibly to behavioral differences between the 
two genders [133].   
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     As mentioned earlier, the effects of lead exposure are worse in children and this is 
related to the total body burden with lead. Affected babies might present with low birth 
weight, failure to thrive and various forms of mental impairment e.g. having learning 
difficulty or low intelligence quotient (IQ) [2, 3, 97]. Other features of lead toxicity in 
children include effects on the mineralization of cartilage and inhibition of the renal 
conversion of vitamin D to its active form, both of which lead to reduced bone density 
and skeletal abnormalities [17]. When the results from 7 international cohort studies 
that examined a total number of 1333 children were compared after making adjustments 
for several variables, it was found out that low blood lead levels even below 7.5 µg/ dL 
were associated with intellectual impairment [134]. The survivors of acute and severe 
lead poisoning in childhood often suffer from life-long sequelae, especially neurological 
and behavioral abnormalities [8]. However, despite the wide range of neurobehavioral 
abnormalities seen in lead poisoning cases, no single feature has been identified as a 
pathognomonic indicator of lead toxicity [17].  
     Based on the previous discussion, both the American Academy of Pediatrics and 
CDC have made a recommendation to screen children, particularly those from 
underprivileged families, for lead levels at the age of 1 and 2 years [17]. In addition, 
preventive public health programs that tackle lead exposure can be very effective and 
productive e.g. reports from the U.S. show that the cost-benefit ratio for reducing lead 
exposure is US $ 1 to 17–220. This ratio is said to be even better than the ratio that is 
obtained from childhood vaccinations [8]. 
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1.3.12. Effects on Women 
     At present, it is suggested that the lower bone lead levels and the higher blood lead 
levels in women are a possible reflection of the differences in the metabolism of lead 
between males and females. These levels might also reflect continuous endogenous 
release of lead from bones in women [135]. A study conducted in 2009 concluded that 
the higher blood lead levels found in 106 pregnant women during their 24
th
 to 28
th
 
weeks of gestation might be an etiological factor for the pregnancy induced 
hypertension (PIH) that they developed [136]. There is also an association between 
gestational lead exposure and miscarriages and preterm deliveries [17]. In addition, 
cumulative lead exposure measured by K-shell X-ray fluorescence was associated with 
an earlier onset of menopause [137]. The chronic (12 months) exposure of female 
Wistar rats to lead acetate resulted in a significant increase in serum luteinizing 
hormone and testosterone levels, and at the same time, caused significant reductions in 
the levels of estradiol and progesterone [138]. 
     The effects of lead may vary, depending on the sex of the exposed species. This was 
demonstrated in a behavioral study, in which rats were exposed to 50 mg/ L of lead 
acetate in drinking water [139]. Compared to females, male rats became hyperactive 
and their spatial memory deteriorated [139]. Lead can also have different effects on the 
progeny of exposed individuals. The exposure of rats in late pregnancy (days 15-21) 
resulted in differential effects on their male and female offspring; as the adult females 
had a suppressed level of type 4 (or delayed type) hypersensitivity reactions and higher 
levels of IL-10, in comparison to the adult males, which had higher IL-12 and lower IL-
10 levels [140]. In addition, when rat pups were exposed to lead in chow for a month, 
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BLL between males and females remained comparable. However, there was a 
differential expression of more than a hundred genes in the hippocampus of these 
animals. This result might demonstrate the importance of sex in determining the 
deleterious effects of lead exposure [141]. 
 
1.3.13. Effects on the Elderly 
     In old age, lead exposure can result in more deleterious effects; given the fragility 
and susceptibility of this vulnerable age group. In this subpopulation, several studies 
such as the normative aging study in the U.S. [142] assessed the cumulative lead levels 
in bones using K-shell X-ray fluorescence. In Korea, researchers identified a positive 
relationship between the exposure to low lead levels in the environment (BLL 2.32 ± 
1.35 μg/ dL) and high blood pressure among the elderly [143].  
     As mentioned earlier, lead competes with both calcium and iron for absorption in the 
GIT. In a related medical condition, known as hemochromatosis, affected subjects have 
increased body burden of iron. A previous study discovered that the elderly, who had 
the hemochromatosis variant genes (C282Y and/or H63D hemochromatosis gene 
(HFE)), had lower levels of lead in the patella [144]. Accordingly, there is a possibility 
that these genes might be responsible for modifying lead‟s toxicokinetics. In 
relationship to the nervous system, environmental exposure in the elderly may impair 
cognitive parameters, especially those related to visuospatial and visuomotor areas 
[142]. In addition, in premenopausal women, a positive association was observed 
between cumulative low level lead exposure, measured in bones, and depression and 
anxiety [145]. 
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1.4. Mechanisms of Toxicity 
     Lead toxicity is dependent upon several factors including the total dose and both of 
the route as well as the duration of exposure. Various mechanisms might be involved in 
lead toxicity e.g. enzymatic suppression; especially for zinc-dependent enzymes [2]. 
The ultimate toxicity may vary from general nonspecific symptoms and signs up to 
fatality [47, 48]. These toxic effects of lead exposure might also be influenced by 
genetic polymorphism [12].  
     The main mechanism underlying lead toxicity is the interference with the normal 
physiology of calcium [48]. As it was mentioned earlier, lead and calcium compete with 
each other for GIT absorption. In normal situations, calcium‟s concentration in the 
extracellular fluid is 10,000 times higher than intracellular levels [146]. In lead 
poisoning, this homeostasis is disrupted. Lead targets anion exchange channels and 
calcium dependent transporters and pumps. Lead also competes with the transportation 
of calcium. Eventually, it replaces calcium [62, 147], thereby exerting its toxic effects. 
Lead can also induce calcium‟s release from the mitochondria [147], thus increasing the 
intracellular concentration of calcium. Additionally, lead has a 100,000 times a stronger 
binding capacity than calcium to calcium-activated proteins [2]. Another mechanism by 
which lead interferes with calcium metabolism is through interacting with vitamin D 
receptor, where polymorphisms of this receptor were found to be associated with high 
lead levels [148].  
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1.5. Measurement of Lead Levels 
     BLLs can be measured using an anodic stripping voltammetry machine, however, 
this equipment has several major problems as it is insensitive, very time consuming, not 
user-friendly, and yields inconsistent results as it is operator-dependent. In comparison, 
the inductively coupled plasma mass spectrometry (ICP-MS) is the state-of-art 
equipment for measuring heavy metals‟ levels whether for clinical practice or 
environmental studies [53]. This method usually requires the use of „sample digestion 
techniques e.g. microwave digestion‟ [53].  ICP-MS has the following advantages [149-
151]: 
- High detection level sensitivity, which is about 10−12 (being better than atomic 
absorption). It is also faster than the latter and can detect many metals in one 
sample in just a few minutes.  
- Its ability to analyze blood, serum, urine and water samples.  
- Detecting a wide range of heavy metals e.g. mercury, arsenic and cadmium, 
thus, being useful for the diagnosis and monitoring of many clinical conditions.  
- It is a computerized system and can analyze hundreds of samples per 24 hours.  
- Many international occupational health organizations such as occupational 
safety and health administration (OSHA) in the U.S. mandate periodic and 
regular medical checkups for workers in hazardous jobs, including the ones that 
involve dealing with heavy metals such as lead. So, ICP-MS helps in complying 
with these agencies‟ mandatory requirements.  
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     Recently, newer methods for the measurement of chronic lead exposures have been 
utilized in various studies. One of these most popular tests in epidemiological studies is 
the use of K-shell X-ray fluorescence for the noninvasive measurement of lead levels in 
bones [152, 153].  
 
1.6. Occupational Lead Exposure in Oman 
     Lead poisoning burdens health facilities and this burden becomes bigger, when 
affected subjects present with chronic complications; particularly if the outcomes are 
serious. According to WHO, lead poisoning contributes 0.6% of the total burden of 
diseases worldwide [154], whereas, Fewtrell [155] estimated that lead exposure is 
responsible for about 1 % of the global burden; mainly in the form of causing mild 
mental retardation and cardiovascular effects. It is estimated that lead exposure-related 
health-issues cost the USA $ 43.5 billion per year [17]. As such, lead toxicity places 
heavy strains on both the financial as well as the human resources of health agencies. In 
Oman, various injuries and poisonings, among which is lead poisoning, resulted in a 
morbidity rate of 883/ 10,000 population in 2009 [156].  In addition, the total 
expenditure of the Omani Ministry of Health in 2008 was about 269 million Rials, 
while the overall cost for services was around 27 million [63].  
     Statistics, published by the Ministry of National Economy in Oman, showed that the 
total number of employees in the subgroup of „manufacturing‟ and the number of 
expatriate employees under „industrial, chemical and food industries occupations‟ in 
2008 were about 85,000 and 42,000 workers, respectively [157, 158]. Furthermore, 
comprehensive occupational health and safety studies ranked number 19 among 30 
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important domains in the Seventh Five Year Health Development and Research Plans 
(2006 – 2010) in the Ministry of Health (MOH) in Oman [159]. All of these facts 
illustrate the importance of occupational health studies in the country so as to protect 
our most valuable resources, the people. 
     So far, there is no data regarding the prevalence of lead exposure among adult 
Omanis in the general population. In collaboration with WHO in 2003, the Department 
of Environmental and Occupational Health (DE&OH) at the MOH examined lead levels 
among 334 school children. The prevalence of lead exposure (BLL ≥ 10 μg/ dL) in this 
age group was found to be 6.58 % [160].  
     Regarding occupational health in Oman, Al-Rusail Industrial Estate (RIE) was 
established in 1983 and since then six more sites were developed throughout the 
country [161]. These are home for many manufacturing companies which deal with 
various metals, for example, lead in Al-Rusail and aluminum in Sohar. Two studies 
conducted at the College of Engineering at Sultan Qaboos University (SQU) and 
published in 2003 could not find significant levels of heavy metals including lead in 
total suspended particulate matter (air samples) that were collected from 23 locations in 
RIE [162], 19 sites in Sohar Industrial Estate and 12 homes in Sohar‟s neighborhood 
[162, 163]. The highest lead level was measured at an automobile battery factory (15.09 
µg/ m³) in Al-Rusail. This was within the acceptable level (an average level of 50 µg/ 
m³ per 8 hour working shift) as set by the U.S. OSHA [162].  
     However, these results do not definitely exclude lead exposure because of several 
reasons. First, these projects neither studied any human subjects nor did they assess the 
relevance of these levels in causing adverse health effects in the exposed workers. 
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Second, lead‟s toxic effects might not necessarily result from acute exposures, but from 
chronic ones that lead to cumulative effects. Within any factory, there is a difference in 
the total concentration between the various workstations, a point that is not specifically 
addressed in the previous studies. In addition, air particles are dispersed over time, and 
thus, their concentrations decrease. This explains the importance of continuous 
measurement and the need for the establishment of surveillance systems. In addition, 
the examined areas in Sohar might have not involved industries related to lead 
exposures.    
     In addition, some data that were obtained directly from the batteries‟ manufacturing 
factory in Oman contradict the findings from the previous studies. These data provide 
clear evidence that lead exposure is still a serious problem at this establishment as they 
showed alarming levels (Tables 1, 2 & 3): 
 
Table 1: Blood lead levels among Omani employees in Reem Batteries Company.  
Blood Lead Levels 
(µg/ dL) 
2008 2010 
Number Percent (%) Number Percent (%) 
< 13 2 1.9 13 10.9 
13 - 39 48 45.7 58 48.7 
40 - 59 39 37.1 36 30.3 
60 - 79 14 13.3 12 10.1 
≥ 80 2 0.9 0 0.0 
Total  105 100  119 100  
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Table 2: Blood lead levels among Reem Batteries Company employees in 2010. 
Blood Lead 
Levels (µg/ dL) 
Number of Workers Total  
Omani Expatriates 
< 10 11 0 11 
10 – 19 12 1 13 
≥ 20 96 123 219 
Total 119 124 243 
 
 
     As mentioned earlier, according to CDC, the cut value of BLL for occupational 
exposures should not exceed 25 µg/ dL [2, 31]. It is medically recommended to relocate 
the workers, who have a BLL of > 60 µg/ dL, to other workstations in order to prevent 
them from being exposed to any more lead [26].     
 
Table 3: Airborne lead levels by section in Reem Batteries Company in 2010. 
Section Airborne Lead Level (µg/ m³) 
Grid casting 94 
Spreading (loading) 260 
Forming & Polishing 264 
Assembling (packaging) 12 
Others 28 
 
 
     From Table 3, it is clearly seen that the employees at the first three work sections are 
exposed to airborne lead levels greater than the permissible values set by OSHA, which 
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should not exceed 50 µg/ m³ per 8 hour working shift. In addition to the manufacturing 
of batteries, occupational lead exposure is an ongoing problem in several other 
occupations e.g. construction and painting. Furthermore, some industries such as 
radiator repair shops are very common and scattered throughout Oman. All these 
workers are exposed to only one type of lead (inorganic lead) and this exposure often 
takes place through the same common route i.e. inhalation.  
     Occupational health nowadays rests heavily on having a solid basis and a strong 
background in ergonomics. However, when fifty managers from different industries in 
Oman participated in a study that was published in 2003, either a lack of knowledge or 
not having informational resources related to ergonomics were reported as the main 
obstacles facing 88 % of the participants [164]. As such, managers should have proper 
training in health and safety.  
 
1.7. Lead Exposure in UAE 
     In the UAE, there are a few published studies that addressed lead exposure issues, 
mainly in Abu Dhabi Emirate. In the general population, a study on school children 
demonstrated an association between high lead levels and attention deficit hyperactivity 
disorder [165]. For occupational exposures, in one cross-sectional pilot study, Bener et 
al. examined a hundred occupationally lead-exposed workers in Al-Ain city and found 
the following results [166]. The exposed group complained of several general and non-
specific symptoms and signs such as GIT disturbance, fatigue, irritability, and memory 
problems, which could be ultimately attributed to lead exposure. The mean BLL in the 
study group was high (77.5 ± 42.8 µg/ dL) and significantly different from the level in 
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the control group (19.8 ± 12.3 µg/ dL). In addition, ALP and LDH levels were 
significantly higher in the workers, in comparison to the control group [167]. Another 
similar study from the UAE reported a mean BLL of  81 µg/ dL among 110 workers, in 
comparison to 11 µg/ dL in age, sex and nationality-matched control group of 110 
people [168]. This study also reported a significant association between BLL and 
systolic and diastolic blood pressures, fasting blood glucose levels, plasma levels of 
total cholesterol, LDH, and uric acid. Thus, it demonstrated a link between lead 
exposure and the risk for developing hypertension and DM. Based on these results, 
there is obviously an ongoing lead exposure problem in the country; and accordingly 
there is a big opportunity to conduct related high quality research and to develop 
practical guidelines and policies in order to deal with this issue successfully.  
 
1.8. Diabetic Animal Models  
     There are many types of diabetic animal models; and each one has its own pros and 
cons. Chemically-induced models have several advantages, and are frequently used. 
These models are usually simple, inexpensive and can be used in rodents as well as in 
higher animals [169]. The two compounds that are most commonly used for this 
purpose are streptozotocin and alloxan [169] and they both can be administered as i.p., 
i.v. or s.c injections [170]. These chemicals are structurally similar to glucose; and 
therefore, they become more effective when they are administered to fasting animals 
[169]. However, alloxan has two main problems. First, it is toxic to the kidneys; and 
second, the animals can recover over time and ultimately become non-diabetic [171]. 
As for STZ, it has a higher level of selectivity to induce DM and is a better agent to be 
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used for the induction of DM in rats [171]. STZ has to be wrapped in aluminum foil in 
order to protect it from light. Because of its instability, it needs to be freshly prepared 
and utilized [169]. STZ model will be discussed in more detail in chapter 4: Diabetic 
Animal Model.  
     On the other hand, the most commonly-used animal models that can spontaneously 
develop type 1 diabetes are the non-obese diabetic (NOD) mouse and bio breeding (BB) 
models [172]. In these models, the individual animals that are more susceptible to 
develop type 1 DM have been carefully selected and bred over and over [171]. Such 
models are helpful in understanding the genetic aspects and the pathogenesis of type 1 
DM [171].  
     In NOD, insulitis starts at around the 3
rd
 or 4
th
 postnatal week, however, full blown 
DM becomes clearly evident around 10 - 14 weeks of age; and it is characterized by 
CD4+ and CD8+ lymphocytic infiltration [169]. Although the NOD model is useful for 
studying the therapeutic potential of new drugs, some medications that were proved to 
be effective in mice were of no use in people [169]. In addition, this model has some 
other disadvantages, for example, it is quite expensive as the mice need to be kept free 
from infections and there is a variability in the incidence of DM in each batch of 
animals [169]. An additional factor to consider is that the incidence of DM in this model 
is higher in female animals than in males [173]. This model is also associated with the 
development of other autoimmune disorders such as thyroiditis [173].  
     In comparison, among the BB model, bio-breeding-diabetes-prone model is 
suggested to be the best type 1 diabetic animal model [171]. This model closely mimics 
human DM on several levels. It develops around adolescence (8-16 weeks in rats), has 
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an equal incidence in male and female rats and leads to severe ketoacidosis that requires 
treatment with insulin, just like in people [171].  
     Other animal models are based on surgical procedures or genetic modifications. 
However, such models require highly advanced techniques, are expensive, and might 
result in the loss of a large number of animals [170]. More recent models involve 
molecular and biological techniques such as the use of knock-in, generalized knock-out, 
and tissue-specific knockout animal models [172].  
 
1.9. Research Problem and Rationale for the Study  
     In brief, lead is a useful heavy metal that has been used in various industries for 
centuries. Because of its widespread distribution in the environment and due to 
manmade activities, exposure to lead has been common and easy. Consequently, this 
resulted in the clinical manifestation of a wide range of poisoning cases. In the past, the 
majority of experimental studies exposed laboratory animals to large doses of lead. 
Also, the vast majority of literature concentrated on studying lead‟s toxic effects mainly 
on the hematopoietic, nervous, renal and cardiovascular systems. However, over time, it 
became evident that lead can basically target all body organs and that no safe level to 
lead exposure could be established. As such, recent studies addressed other problems 
e.g. lead‟s effects on the pituitary-thyroid pathway. In addition, there is an increasing 
interest in the immunological and allergenic potential of heavy metals, which has been 
recently reported in a few published studies. Besides determining lead‟s toxic effects, 
addressing its mechanisms of actions that yield such effects is obviously also worth 
examining.  
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     There are some cross-sectional studies that looked at the relationship between lead 
exposure and its effects on the thyroid glands, however, the results from such studies 
have several limitations related to sample size, total duration of exposure and other 
cofounders e.g. smoking habits of the participants. In order to have firm answers, some 
animal studies also addressed this issue. Until today, however, this topic remains 
controversial. Accordingly, the lack of adequate data and the inconsistency in literature 
in regard with the relationship between lead exposure and its effects on the pituitary-
thyroid pathway stimulated us to conduct this study. In addition, the U.S. ATSDR stated 
that „the information regarding effects of lead on the liver in humans and animals is 
scarce and does not allow for generalizations‟ [174]. Besides, little is known about the 
association between lead exposure and inflammatory markers [175, 176]. Therefore, 
experimental studies that explore the effect of lead exposure on thyroid functions, 
inflammation, and hepatic and systemic toxicity are much needed.  
     In this thesis, we determined the toxic effects of lead exposure in normal rats and 
diabetic rats. Diabetes was selected because of several reasons. First, according to our 
knowledge, the relationship between these two conditions (i.e. lead exposure and DM) 
has not been addressed before in experimental work. Second, DM is a major global 
health problem. Third, there is a large prevalence of this condition in the UAE. In 
addition, there is a close association between thyroid disorders and DM in clinical and 
epidemiological studies. Although there are several diabetic animal models, we studied 
the effects of lead in STZ-induced diabetic Wistar rats; since this model is well 
established and it has been used successfully in our laboratory.  
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1.10. Aims and Objectives 
     The main aim of this thesis was to determine the toxic effects of exposure to several 
doses of lead acetate trihydrate on the pituitary-thyroid pathway in normal and diabetic 
rats. We also documented systemic effects on other major organs. The specific 
objectives were as follows: 
- Studying the toxic effects of lead exposure in healthy Wistar rats 
- Investigating the toxic effects of lead exposure in STZ-induced diabetic rats 
- Developing a new experimental thyroid model based on the use of hormones, 
where TRH is used to induce hyperthyroidism and OCT is utilized for the 
induction of hypothyroidism 
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Chapter 2: Materials and Methods 
      
     This study was approved by the Research Ethics Committee (Institutional Review 
Board) at the College of Medicine and Health Sciences, UAE University. 
 
2.1. Animals 
     Young male Wistar rats were used in all experiments. They were housed in 
polypropylene plastic cages and kept in 12 hour cycles of light and dark at 22 ± 2 ᴼC. 
They were supplied with chow and tap drinking water ad libitum. The animals were 
handled in a humane way to minimize suffering and pain. The weight of all animals was 
assessed on the first and last days of experiments.  
 
2.2. Study Design 
2.2.1. Non-Diabetic Model 
2.2.1.1. Treatment Protocol 
     Young male Wistar rats, with a weight range of 208 to 253 grams, were used per the 
following treatment protocol, as shown in (Table 4). The daily treatments of either 
distilled water (DW) or the various doses of lead acetate trihydrate were given as i.p. 
injections for a total duration of five days. Animals in the control group received DW, 
whereas, the animals in the four treatment groups A, B, C and D were given 1, 25, 50, 
and 100 mg/ kg of lead acetate trihydrate, respectively. These doses are among the 
standard and effective doses that have been used in lead studies [64, 177]. 
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Table 4: Treatment protocol in non-diabetic animals.  
All animals were treated with i.p. injections for five days. The control group received 
DW, whereas, the animals in treatment groups A, B, C and D were treated with 1, 25, 
50, and 100 mg/ kg of lead acetate trihydrate, respectively. 
 
Groups 
 
5 Days Treatment 
Lead Dose (mg/ kg), i.p. 
Control DW 
A 1 
B 25 
C 50 
D 100 
 
     
     The LD50 through the i.p. route in rats is 150 mg/ kg for lead acetate and 200 mg/ kg 
for lead acetate trihydrate [178], which is a more soluble form of the compound and is 
miscible with water [179]. Since the LD50 of lead acetate trihydrate is in the range of 50 
- 500 mg/ kg, this chemical is considered to be moderately toxic [180]. Accordingly, the 
doses that we used in our experiments represent the following percentages of LD50 of 
lead acetate trihydrate (Table 5). 
 
Table 5: The relationship between lead acetate trihydrate doses and LD50 (%). 
 
Dose (mg/ kg) Percentage of LD50 (%) 
1 0.5  
25 12.50 
50 25.00 
100 50.00 
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2.2.2. Diabetic Model 
2.2.2.1. Induction of Diabetes Mellitus  
     Type I diabetes was induced in one month old rats by treatment with a single dose of 
60 mg/ kg STZ freshly prepared in citrate buffer, given as i.p. injections. The animals 
were monitored and their weight was recorded on a weekly basis. Six weeks later and 
just before the start of experiments, blood samples from the tail were examined for 
random blood sugar (RBS) levels using an Accucheck performa glucometer (Roche 
Diagnostics, NSW, Australia). The cut value for diagnosing diabetes was set at 300 mg/ 
dL and the animals that had not become diabetic were excluded. The weight of the 
animals was monitored before the induction of DM and throughout until the last day of 
experiments.  
  
2.2.2.2. Treatment Protocol 
     The treatment protocol that we used in STZ-induced diabetic rats was similar to the 
one used for non-diabetic animals, except that we did not have the treatment group of 1 
mg/ kg lead acetate as is shown in (Table 6). We excluded this group because we did 
not get significant results in the 1 mg/ kg lead acetate non-diabetic group. Six weeks 
post DM induction with STZ, the animals were divided into four groups i.e. the control 
group was also a diabetic group. All groups were treated with daily i.p. injections for 
five days. Control group animals were given DW. The three treatment groups received 
25, 50, and 100 mg/ kg of lead acetate trihydrate, respectively.   
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Table 6: Treatment protocol in diabetic animals.  
The control group was treated with daily i.p. injections of DW for five days. Treatment 
groups A, B and C were given 25, 50, and 100 mg/ kg of lead acetate trihydrate, 
respectively. 
 
Groups 
 
5 Days Treatment 
Lead Dose (mg/ kg), i.p. 
Control DW 
A 25 
B 50 
C 100 
 
 
 
2.2.3. Hormonal Thyroid Model 
2.2.3.1. Treatment Protocol 
     These animals were treated for five days with i.p. injections (Table 7). DW was 
administered to the control group. The TRH group received 5 µg of TRH / 100 g body 
weight, whereas, OCT group was treated with 10 µg of OCT/ kg body weight. 
 
Table 7: Treatment protocol for hormonal thyroid model.  
All animals were treated for five days. The control group received i.p. DW, TRH group 
was treated with TRH at a dose of 5 µg/ 100 g body weight i.p., and OCT group was 
given 10 µg of OCT/ kg, i.p., respectively. 
 
Groups 
 
5 Days Treatment, i.p. 
Control DW 
TRH TRH 
OCT OCT 
 
 
2.3. Chemicals   
     Lead acetate trihydrate was purchased from Sigma, Aldrich (Missouri, USA). For 
determination of BLL by using an ICP-MS, the following chemicals were utilized. 
Double distilled nitric acid, tetra methyl ammonium hydroxide (TMAH), triton X-100, 
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and EDTA disodium salt; all were TraceSelect® grade and were obtained from Sigma-
Aldrich (St. Louis, MO, USA). Lead, the primary standard and Rhodium, the internal 
standard, were PE Pure® grade and obtained from PerkinElmer (CT, USA). Standard 
reference materials (SRM) Sero Whole Blood level 2 were obtained from Seronorm® 
(Sero, Norway). Pure water was supplied through our lab resources and equipped with 
MilliQ Millipore® laboratory pure water (>18 MOhms).  
 
2.4. Blood Samples 
     Blood samples were collected within half an hour to one hour after injecting the 
animals with the last dose on day 5 between 9.00 a.m. to 1.00 p.m. Before collecting the 
samples and sacrificing of the animals, sodium pentobarbital (70 mg/ kg) was 
administered as a general anesthetic. Following laparotomy, the samples were collected 
from the inferior vena cava in syringes containing 4% sodium citrate as an 
anticoagulant. Fresh whole blood samples were used to determine complete blood 
counts (CBC). The rest of blood samples were centrifuged at 3000 g for 10 minutes. 
The separated plasma and a portion of whole blood samples, that were used to 
determine BLL, were stored at -80.0 ºC pending analysis.  
 
2.5. Assessment of BLL 
     BLL in whole blood samples were determined by using a modified version of the 
ICP-MS method, described by Nunes, J.A., et al. [181]. All the analyses were performed 
on a PerkinElmer Nexion 300® equipped with nickel sampler and skimmer cones, 
standard Ryton Double-Pass Scott-type spray chamber, standard ceramic injector, and 
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Meinhard® Concentric nebulizer. The instrument was equipped with an S-10 
autosampler (PerkinElmer), and software version is Nexion®. Lead is monitored at its 
three major isotopes: m/ z 208, 207 and 206.   
Lead Calibration Standards: Lead calibration standards were prepared from dilution 
of 1000 mg/ L lead primary standard (PE Pure, PerkinElmer) at 10, 50, 100 and 500 ppb 
(μg/ L) levels. For instrumental calibration, these stock standards were diluted 1:100 in 
the above diluent solution. The calibration blank was made up of the diluent solution. 
Diluent: The blood diluent consists of 0.005% w/v Triton-X-100 and 0.05% EDTA. 
Both of TraceSelect® and Sigma Chemicals were prepared in MilliQ Millipore® 
laboratory pure water (> 18 MOhms).    
Sample Preparation: All calibration standards, quality control materials (QCs), 
standard reference materials (SRMs), blanks, and unknown blood samples were 
equilibrated to room temperature prior to sampling. Blood samples (200 μL), were 
pipetted into (15 mL) conical tubes. Then, 500 μL of 10% v/v TMAH solution was 
added to the samples, incubated at room temperature for 10 min, and then the volume 
was made up to 10 mL with a solution containing 0.05% w/v EDTA + 0.005% v/v 
Triton X-100. Rhodium was added as internal standard to obtain a final concentration of 
10 μg/ L. After that, samples were directly analyzed by ICP-MS.  
 
2.6. Assessment of Hormonal Levels 
     TSH ELISA kits for rats were purchased from USCN Life Science Inc. (Wuhan, 
China), whereas total T3 and total T4 ELISA kits for rats were obtained from 
MyBioSource Company (California, USA). The plasma samples were analyzed 
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according to the relevant company‟s manuals.  
 
2.7. Assessment of GSH 
     Glutathione levels in plasma were determined, using a kit from Sigma Aldrich 
(Missouri, USA) and following the manufacturer‟s instructions as described before 
[182].  
 
2.8. Assessment of Complete Blood Counts (CBC) 
     CBC parameters in whole blood samples were determined using ABX VET ABC 
Hematology Analyzer machine from ABX Diagnostics (Montpellier, France), with a 
special analysis card for rats.  
 
2.9. Assessment of Biochemistry Parameters 
     A total of 10 renal and hepatic function parameters in plasma were determined using 
Cobas Integra 400 biochemistry analyzer from Roche (Indianapolis, USA). These 
parameters are blood urea, creatinine (CRE), albumin (ALB), alkaline phosphatase 
(ALP), alanine Aminotransferase (ALT), aspartate aminotransferase (AST), lactate 
dehydrogenase (LDH), C-reactive protein (CRP), total bilirubin, and total proteins. 
  
2.10. Statistical Analysis 
     Statistical analysis was performed using GraphPad Prism 5 for Windows, version 
5.01, 2007. The various treatment groups i.e. lead doses, represent the independent 
variable, which was compared with the resultant and dependent variables e.g. levels of 
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thyroid hormones and biochemistry parameters. In the hormonal model, two-way 
ANOVA was used to analyze weight changes during the five days of treatment with 
lead acetate, whereas, for all the remaining parameters, one way ANOVA was used. 
This was followed with Bonferroni post-hoc test for selected groups to compare the 
control group with each treatment group in sequence. Results are presented as mean ± 
standard error of the mean (SEM).  
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Chapter 3: Lead’s Effect in Non-Diabetic Model 
 
3.1. Background  
     Chronic lead exposure causes multiple systemic toxicities, particularly affecting the 
hematopoietic, nervous, and renal systems [1, 183]. These effects are related to the total 
body burden with lead and are worse in children. In the initial stages and at minimal 
levels of exposure, clinical presentation is vague and nonspecific and can easily pass 
unrecognized [1]. Systemic and more specific features become evident at higher levels 
of exposure. For example, inhibition of the enzymes that are involved in the heme 
synthesis pathway elevate the levels of 5-aminolaevulinic acid in urine and zinc 
protoporphyrin in blood [184], both of which might be used as diagnostic parameters 
for lead poisoning. The resultant anemia is usually a late manifestation of lead 
poisoning [185]. Acute lead exposure can also result in elevated blood pressure, with a 
particular increase of systolic blood pressure [186, 187], which might be either a cause 
for or a sequela of renal damage. Lead encephalopathy is one of the most dreaded 
serious complications of acute lead toxicity [19, 73, 74]. In regard with lead toxicity, the 
nervous system is considered to be the „critical organ‟ that is at risk when the blood lead 
level (BLL) is at a „critical level‟ of 10.7 – 17.5 µg/ dL [188].    
     Despite the widespread multi-organ nature of lead toxicity, evidence of effects on the 
thyroid gland is still not elucidated since no definitive relationship has been confirmed 
yet as the limited studies that have been previously conducted showed contradicting and 
inconclusive results [189]. For example, among occupationally exposed workers, 
elevated BLL of more than 80 µg/ dL were associated with significantly high levels of 
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thyroid stimulating hormone (TSH), whereas, in the lower BLL groups (40-59 and 60-
79 µg/ dL groups), TSH levels were lower and comparable between the two groups 
[190]. In another occupational study, in which 137 lead-exposed workers were 
compared with 83 controls, no statistical difference in (thyroxine) T4 levels was found 
between the two groups [191].  
     Although these cross-sectional studies addressed the relationship between lead 
exposure and thyroid effects, such studies cannot differentiate between causality and 
effect. In addition, there might be other confounding factors in these studies e.g. age of 
participants, variable durations of cumulative occupational exposures and smoking 
habits.  
     Experimental animal studies also showed variable results e.g. the daily 
administration of 5 mg/ kg of lead acetate orally to sheep over 8 weeks resulted in a 
reduction in all thyroid-related main parameters i.e. TSH, T4 and triiodothyronine (T3) 
[192]. Similar results were also obtained in lead-exposed rats [193]. In comparison, 
there were no effects on T3 and T4 levels when rats were exposed to lead acetate in 
drinking water for three months [194].  
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3.2. Results 
3.2.1. Weight Monitoring  
     Animals in the control group, as expected, gained some weight (Figure 2), whereas, 
in the group that was treated with 1 mg/ kg of lead acetate, weight loss was slight and 
insignificant. However, there was a significant amount of weight loss in the remaining 
groups i.e. the ones that were treated with 25, 50 and 100 mg/ kg of lead acetate; and 
the highest amount of weight loss was observed in the group that was treated with 100 
mg/ kg of lead acetate.   
 
Figure 2: Weight change in non-diabetic animals. 
Percentage of body weight change over five days of treatment. One-way ANOVA test, 
followed by Bonferroni post-hoc test for selected groups are used. Results represent 
mean ± SEM, (n= 4-10), *: p < 0.05, and ***: p < 0.001 
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3.2.2. BLL Results 
     No measurable BLL were detected in the control group. BLL in the animals, which 
were exposed to 1 mg/ kg of lead acetate, were not significantly affected compared with 
the control group (Figure 3). However, animals receiving 25, 50, 100 mg/ kg of lead 
acetate had significantly high BLL, in comparison to the control group. 
 
Figure 3: Blood lead levels in don-diabetic animals.  
One-way ANOVA test, followed by Bonferroni post-hoc test for selected groups are 
used. Results represent mean ± SEM, (n= 3-5), and ***: p < 0.001 
 
3.2.3. Thyroid Function Tests 
     Compared with the control group, TSH concentrations in the group, which was 
treated with 1 mg/ kg of lead acetate, were statistically not affected (Figure 4 A). The 
groups that received higher doses of lead acetate (25, 50, 100 mg/ kg) had a significant 
increase in TSH concentrations. However, with regard to thyroid hormones, no 
significant effects on T4 and T3 levels were detected at any used dose of lead (Figure 4 
B & C).   
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Figure 4: Thyroid function tests in non-diabetic animals. 
Levels of (A) TSH. (B) T4. (C) T3. One-way ANOVA test, followed by Bonferroni 
post-hoc test for selected groups are used. Results represent mean ± SEM, (n= 5-10), 
and *: p < 0.05, **: p < 0.01 
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3.2.4. GSH Levels in Plasma     
     Rats exposed to 1 mg/ kg of lead acetate showed a significant increase in GSH 
levels, compared to the control group; however, no significant effects on GSH were 
observed at higher doses of lead acetate exposure (Figure 5).  
 
 
Figure 5: GSH levels in non-diabetic animals. 
One-way ANOVA test, followed by Bonferroni post-hoc test for selected groups are 
used. Results represent mean ± SEM, (n= 5-9), and **: p < 0.01 
 
3.2.5. CBC Results 
     We observed a gradual increase in WBC counts with increasing doses of lead 
acetate; however, the result was statistically significant only in the group receiving 100 
mg/ kg of lead acetate (Figure 6 A). On the other hand, platelet counts were 
significantly reduced in rats that were treated with 100 mg/ kg of lead acetate (Figure 6 
B). The current protocol did not affect hemoglobin levels, hematocrit percentage, or 
RBC counts (Figure 7 A-C). 
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Figure 6: WBC and platelet counts in non-diabetic animals. 
(A) WBC counts. (B) Platelet counts. One-way ANOVA test, and Bonferroni post-hoc 
test for selected groups are used. Results represent mean ± SEM, (n= 5-10), and *: p < 
0.05 
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Figure 7: Hemoglobin, hematocrit and RBC counts in non-diabetic animals. 
(A) Hemoglobin levels (B) Hematocrit percentage. (C) RBC counts. One-way ANOVA 
test, and Bonferroni post-hoc test for selected groups are used. Results represent mean ± 
SEM, (n= 5-10) 
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3.2.6. Biochemistry Parameters 
     Treatment with increasing doses of lead acetate resulted in significant effects on 
several biochemical parameters (Figure 8) and (Figure 9). LDH activity was 
significantly raised in rats exposed to 50 and 100 mg/ kg of lead acetate (Figure 8 A). 
Both AST and total bilirubin were elevated in the group that was treated with 100 mg/ 
kg of lead acetate (Figure 8 B & C). CRP concentrations were significantly high in the 
groups that received 25 and 50 mg/ kg of lead acetate (Figure 8 D). Although the groups 
that received lead doses of 25 mg/ kg or higher had lower levels of ALP, the results 
were not significant (Figure 9 A). ALT levels were not affected and neither albumin nor 
total protein levels were affected by lead exposure for five days (Figure 9 B - D).  
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Figure 8: Levels of LDH, AST, total bilirubin and CRP in non-diabetic animals. 
Levels of (A) LDH. (B) AST. (C) Total bilirubin. (D) CRP. One-way ANOVA test, 
followed by Bonferroni post-hoc test for selected groups are used. Results represent 
mean ± SEM, (n= 4-11), and *: p < 0.05 
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Figure 9: Levels of ALP, ALT, albumin and total proteins in non-diabetic animals. 
Levels of (A) ALP. (B) ALT. (C) Albumin. (D) Total Proteins. One-way ANOVA test, 
followed by Bonferroni post-hoc test for selected groups are used. Results represent 
mean ± SEM, (n= 4-11) 
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     Relative to renal functions, urea levels increased significantly in the group treated 
with 100 mg/ kg of lead acetate (Figure 10 A). Compared with the control group, 
creatinine levels remained statistically insignificant (Figure 10 B). 
 
 
Figure 10: Urea and creatinine levels in non-diabetic animals. 
(A) Urea levels. (B) Creatinine levels. One-way ANOVA test, followed by Bonferroni 
post-hoc test for selected groups are used. Results represent mean ± SEM, (n= 6-11), 
and *: p < 0.05 
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3.3. Discussion 
     In this model, we demonstrated that lead acetate exposure increased the secretion of 
TSH from the anterior pituitary gland. It also caused impairments in renal and hepatic 
functions. Moreover, markers of oxidative stress (GSH) and inflammation (WBC and 
CRP) increased in response to lead exposure.    
     As the dose of lead increased, evident from BLL, animals lost more and more 
weight. Weight loss might be attributed to several factors e.g. the multisystemic toxic 
effects of lead exposure, and muscle and fat wastage. In addition, sick animals often 
lose appetite and have low food intake. Previous occupational-exposure studies have 
shown that parental lead exposure, both maternal [195] and paternal [196], is associated 
a reduction in the birth-weight of their infants. In comparison, when rats were exposed 
for one month to either 50 mg/ L of lead acetate in drinking water given ad libitum 
[197] or treated with daily intramuscular injections of lead acetate (first dose 4 mg/ 100 
g, later doses 0.05 mg/100 g) [198], no significant effects on weight were observed.  
     In our study, BLL corresponded directly with the administered doses of lead acetate. 
The increases in BLL in a dose-response manner demonstrate the effectiveness and 
usefulness of i.p. route administration and the level of absorption of lead acetate 
through this route. Although this is not the natural route of exposure to lead in humans, 
the advantage of using i.p. injections is that it eliminates the differences in exposure 
levels compared to ad libitum oral exposures.  
     In order to convert the measured BLL in ppb to µg/ dL, which is the unit of 
measurement for BLL in clinical settings, we used the conversion factor: 1 µg/ dL = 10 
ppb [199, 200]. As such, the measured BLL (in ppb) in the four treatment groups 
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correspond to the following clinically equivalent values: 25, 100, 181, and 205 µg/ dL, 
respectively. For diagnostic purposes, 25 µg/ dL of BLL is considered a mild condition, 
whereas, any value exceeding 80 µg/ dL represents a severe condition and might result 
in life threatening medical emergencies e.g. encephalopathy [201].  
     The hypothalamus-pituitary-thyroid axis is controlled by three mechanisms. The first 
one is the long loop i.e. thyroid hormones acting on the hypothalamus. There is also 
some control from the pituitary to the hypothalamus through the short loop. The last 
mechanism is within either the hypothalamus or pituitary (ultra-short loop) [202].  
     Our data show that lead exposure resulted in a clear dose-response effect on the 
anterior pituitary, causing an elevation in TSH levels. On the other hand, thyroid 
hormones, T4 and T3, were not affected. These findings, the combination of high TSH 
and normal T4 and T3 levels, are in line with a common clinical presentation, known as 
„subclinical hypothyroidism‟ [203], which is considered to be a „compensatory stage‟ 
that maintains thyroid hormones within normal levels [204]. This condition, which is 
often associated with autoimmune abnormalities or the use of exogenous drugs, is the 
early stage and a risk factor for developing full-blown hypothyroidism [31, 203].  
     The increasing TSH levels observed might demonstrate a direct stimulatory effect of 
lead on the anterior pituitary. High TSH levels might also indicate a disturbance in the 
mechanisms that control the long feedback loop process, whereby the hypothalamus and 
the pituitary fine-tune and decrease TSH secretion when T4 and T3 levels are normal 
[205]. Alternatively, there might be an interruption in the signaling process of the 
downward pathway from the pituitary; that is why high TSH levels could not induce an 
increased secretion of T4 and T3 [205]. In addition, the feedback control system is 
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relatively slow and can take some time until the features and signs of overt 
hypothyroidism are seen, and this gives rise to the biochemical presentation of 
subclinical hypothyroidism [206]. It has been also reported that TSH is secreted as a 
mixture of isoforms and this might result in having variable biological effects [207]. 
Apart from the stimulatory effects of TSH on the thyroid, other factors e.g. 
thyroglobulin can exert a negative feedback effect on the thyroid gland [208].  
     In regard to thyroid parameters, previous studies showed variable results. For 
instance, in an occupational-health cross-sectional study, 58 male workers with an 
average BLL of 51.9 µg/ dL were found to have high TSH levels and no effects on T4 
and T3 levels [209]. In another occupational setting, high BLL of more than 60 µg/ dL 
were associated with a reduction in total and free T3 levels [210]. Yet, other studies in 
similar environments could not demonstrate any associations at all in workers with BLL 
of up to 75 µg/ dL [211, 212]. Finally, when Sprague Dawley rats were exposed to 25, 
50 and 100 mg/ kg of lead acetate, the results showed a significant increase in TSH and 
a reduction in both of T3 and T4 levels in serum [213].   
     Glutathione (GSH) is one of the main defense mechanisms against reactive oxygen 
species (ROS) in our bodies. Our results showed that a low dose of lead treatment i.e. 1 
mg/ kg stimulated the animals to increase the production of GSH, thereby counteracting 
the toxic effects of lead exposure and avoiding any damage to the tissues. Higher doses 
of lead acetate (25, 50, 100 mg/ kg) resulted in a reduction in GSH levels, albeit not 
statistically significant. Dewanjee, S., et al. [214] has shown that longer periods (40 
days) of lead exposure caused significant depletions of GSH stores in several organs 
including the kidneys, liver, heart, and brain. The cause for this discrepancy might be 
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related to the difference in exposure periods (in our case 5 days of treatment) and to the 
fact that we measured GSH levels in plasma and not in tissues. As such, additional 
studies are needed to clarify this issue.  
     Our data showed an increase in WBC counts and CRP levels, which is a clear 
indication of the possibility of an inflammatory reaction in response to lead exposure. 
The increased level of CRP observed in our study is consistent with a few, recently-
published studies, which were conducted in the general population [176] and in 
occupational settings [215]. Taken together, these findings suggest that inflammation 
might represent a possible mechanism for the adverse health effects of lead toxicity.  
     In this study, lead exposure resulted in a general trend of low platelet levels. This 
could be due to an inhibitory effect on the bone marrow, leading to decreased platelet 
production [216]. It can also indicate platelet activation in vivo. Moreover, it has been 
reported that exposure to lead caused an increase in pro-thrombotic effects in mice [217, 
218]. A very recent study on occupationally exposed workers to lead-acid batteries 
demonstrated a similar reduction in platelet counts [219]. In addition, it has been 
previously demonstrated that exposure to other environmental pollutants such as 
ultrafine particles also caused a decrease in platelet numbers in patients with 
cardiovascular disease [220]. Furthermore, the intra-tracheal instillation of a single dose 
of diesel exhaust particles decreased platelet numbers in type 1 diabetic mice [221].  
     In the present study, we assessed the effects of lead exposure on the liver and 
kidneys. This is because among soft tissues, the liver is the most important storage site 
for lead [174]. Regardless of the route of exposure, inorganic lead is eventually excreted 
unchanged mainly in either urine or bile [175]. Also, it has been reported that a 
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significant amount of T4 is converted into T3 in these organs [222].  
     Higher doses of lead acetate caused an elevation in the levels of two hepatic 
enzymes, namely LDH and AST. These markers are released into the bloodstream 
whenever there is tissue breakdown [223, 224]. Similarly, the increase in total bilirubin 
levels also results from hepatocytes‟ damage [224, 225]. Since conjugated bilirubin is 
water-soluble and will be eventually excreted in urine, high levels of total bilirubin can 
indicate a failure in the glucuronidation and conversion process of unconjugated 
bilirubin to the conjugated one [226]. Thereby, total bilirubin levels build up in the 
circulation. In normal situations, heme oxygenase converts heme into bilirubin. 
Exposure to lead in animal studies activated this reaction i.e. lead exposure increases 
bilirubin levels [47, 227]. Previous studies of occupationally exposed workers and 
animal experiments observed a similar increase in AST, ALT, and total bilirubin levels 
[192, 228, 229]. In contrast, another occupational health study could not find any effects 
on cholesterol, LDH, and ALP levels [230].    
     In contrast, the synthetic abilities of the liver, manifested by albumin and total 
protein levels, are still well preserved at this stage. These functions might deteriorate 
only in chronic lead exposures, which are often accompanied by severe malnutrition or 
advanced disease status. As such, chronic exposures in Indian workers were associated 
with low total protein and albumin levels [228]. Similarly, chronic lead exposure of 
laboratory animals led to a reduction in total proteins [214].  
     After circulating in the body, a significant amount of lead is filtrated in the glomeruli 
and excreted unchanged in urine [47]. The increase in urea levels, observed in our 
study, is an indication of renal dysfunction. Regarding creatinine, its total blood levels 
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represent the overall levels, released from various tissues including kidneys, heart and 
skeletal muscles. Although renal impairment is often associated with an increase in 
creatinine levels, the latter remained insignificant in this study. This might be due to 
reduced muscle bulk, seen as weight loss. Similar results of no effects on creatinine 
levels were obtained when rats were treated with 8 mg/ kg of lead acetate i.p. for two 
weeks [231].     
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3.4. Conclusion 
     In this model, our results showed that lead exposure had significant effects on many 
systemic parameters. These included causing an elevation in TSH secretion from the 
anterior pituitary gland. In addition, lead exposure negatively affected the functions of 
the liver and kidneys. In addition, oxidative stress markers e.g. GSH and inflammatory 
parameters i.e. WBC and CRP were increased.   
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Chapter 4: Lead’s Effects in Diabetic Model 
 
4.1. Background 
     Being a ubiquitous element in the environment, lead causes toxic effects to various 
organ systems. Although environmental lead exposures are common, the most 
important sources currently are occupational settings [2], which usually involve 
exposures to inorganic lead [3, 32]. 
      Over the last few decades, modern lifestyles have increased the prevalence of 
several non-communicable multisystemic diseases including diabetes mellitus (DM). In 
2008, there were about 347 million people with diabetes [169]. According to WHO, the 
worldwide prevalence of DM in 2014 was 9% in adults aged 18 years or older, and 90% 
of these cases are type 2 diabetes [232]. WHO also estimated that DM was a direct 
cause for 1.5 million fatalities in 2012, and the majority (80%) of these deaths took 
place in low to middle income regions of the world [232]. Diabetes is a risk factor for 
cardiovascular diseases, neuropathies, and is also a main cause for blindness, 
amputations and renal failure [232]. In addition, the risk of death in diabetics is twice in 
comparison to the risk in non-diabetic people [232]. In the UAE, the prevalence of DM 
among expatriates ranges from 13 to 19%, obviously depending on their genetic 
backgrounds. On the other hand, 25% of Emiratis are diabetic [233]. With such high 
levels, the UAE has the second highest global prevalence of DM [234]. Because of the 
seriousness of this condition, WHO and in collaboration with the international diabetes 
federation designated the 14
th
 of November of each year as „world diabetes day‟ in 
order to raise awareness and to advocate for the prevention and the proper management 
of DM [232].  
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     It has been estimated that thyroid disorders would eventually develop in about one 
third of type I diabetic patients [235], indicating that there is a strong association 
between these two conditions. In Spain, the annual incidence of thyroid dysfunction in 
patients with Type II diabetes was reported to be around 10%, whereas its prevalence 
was about 32% [236].  
     In experimental animal research, streptozocin (STZ), which is an alkylating agent 
that causes DNA damage, cross-linking [237], DNA strand breaks [172], and eventually 
DNA destruction and thus cell death [170], is frequently used for studying type I 
(insulin dependent) diabetes mellitus [238]. STZ also causes depletion of NAD and 
ATP, which will at the end lead to a cessation in insulin secretion and the development 
of type 1 DM [169]. Diabetes will develop within few days post STZ-injection; usually 
4 days in mice and 7 days in rats [170]. STZ can be administered either as a single or 
multiple doses [169]. Being similar to the natural disease, this model can also induce an 
immune-mediated reaction [172] and can affect the thyroid functions of the treated 
animals. Because of the oncogenic features of STZ, it can lead to the development of 
hepatic and renal tumors [170]. Other STZ disadvantages include the possibility of 
spontaneous regeneration of beta cells in the pancreas and having low lymphocyte 
counts [169].  
     When 80 mg/ kg of STZ was given through sublingual injections, T3 levels in 
Sprague-Dawley (SD) rats had a statistically significant drop only during the first two 
weeks of induced DM, whereas, T4 levels remained low throughout the 7 weeks of 
assessment i.e. the levels of only the biologically active hormone, namely T3, were 
maintained [239].  
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     Histological studies of thyroid glands showed that exposure to lead acetate can cause 
hypertrophy of the follicular epithelial cells, enlargement in the volume of follicles and 
reduced staining, which indicates low thyroglobulin levels [240, 241]. There might also 
be excessive fibrotic tissue formation due to necrosis [240].  
     Currently, oxidative stress is correlated with a variety of pathological conditions and 
complications including type 1 and 2 of DM [242, 243]. In addition, because of the 
intrinsic nature of the synthesis of thyroid hormones since iodide has to be oxidized 
first, interactions with reactive oxygen species (ROS) such as the oxidizing agent 
hydrogen peroxide (H₂O₂) may obviously result in glandular pathologies [244]. Many 
thyroid abnormalities such as overt hypothyroidism, Graves' disease, and Hashimoto 
thyroiditis have been associated with oxidative stress as the levels of SOD were found 
to be elevated [245, 246].  
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4.2. Results 
4.2.1. Weight Monitoring  
     The initial weight (before the induction of DM) of the adult male Wistar rats, used in 
this experiment, ranged from 216 to 288 grams. A week later, there was a significant 
drop in the weight of these animals (Figure 11). Then over the next few weeks, the 
animals regained some weight.  
 
Figure 11: Weight change post DM induction in diabetic animals. 
The mean change in weight of all animals over the six weeks post DM induction, the 
initial weight in week 1 versus the weight in each subsequent week are compared. One-
way ANOVA test, followed by Bonferroni post-hoc test for selected groups are used. 
Results represent mean ± SEM, (n= 45), *: p < 0.05 
 
     During the experiments, the diabetic control group maintained its weight throughout 
the five days of treatment. However, treatment of the diabetic rats with various doses of 
lead acetate (25, 50, and 100 mg/ kg) resulted in significant reductions in the weight of 
these animals (Figure 12). The group that was treated with 100 mg/ kg of lead acetate 
had the highest amount of weight loss.  
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Figure 12: Weight change over five days of treatment in diabetic animals. 
Percentage of body weight change over five days of treatment. One-way ANOVA test, 
followed by Bonferroni post-hoc test for selected groups are used. Results represent 
mean ± SEM, (n= 9), and ***: p < 0.001 
 
4.2.2. RBS Results: 
     Six weeks post DM induction; the animals had an RBS level ranging from 394.0 to 
600.0 mg/ dL with a mean level of 546.3 ± 8.9 mg/ dL.   
 
4.2.3. BLL Results 
     The control group did not have any detectable BLL (Figure 13). In comparison, the 
groups that were treated with lead acetate had increasing and statistically significant 
72 
  
BLL. Treatment of the rats with 25, 50, and 100 mg/ kg of lead acetate caused BLL of 
1228, 1498, and 2330 ppb, respectively. 
 
Figure 13: Blood lead levels in diabetic animals. 
Blood lead levels (BLL). One-way ANOVA test, followed by Bonferroni post-hoc test 
for selected groups are used. Results represent mean ± SEM, (n= 4-7), and **: p < 0.01, 
***: p < 0.001 
 
4.2.4. Thyroid Function Tests 
     There was an increase in TSH levels in the groups that were treated with 50 and 100 
mg/ kg of lead acetate, compared with the control group (Figure 14 A). However, the 
level was statistically significant only in the group that received the highest dose. On 
the other hand, treatment with 50 and 100 mg/ kg of lead acetate caused a statistically 
significant reduction in T4 levels (Figure 14 B). Similarly, the decrease in T3 levels was 
significant only in these same two groups i.e. 50 and 100 mg/ kg of lead acetate (Figure 
14 C).  
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Figure 14: Thyroid function tests in diabetic animals. 
Levels of (A) TSH. (B) T4. (C) T3. One-way ANOVA test, followed by Bonferroni 
post-hoc test for selected groups are used. Results represent mean ± SEM, (n= 5-10), 
and *: p < 0.05, **: p < 0.01, and ***: p < 0.001 
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4.2.5. Oxidative Stress Markers in Plasma 
     Compared to the control group, there was a reduction in GSH levels in all treated 
groups; however, the low levels were statistically significant only in the groups that 
received high lead acetate doses (50 and 100 mg/ kg) (Figure 15 A).  
     On the other hand, regarding MDA levels, no statistically significant results were 
observed in the various treatment groups (Figure 15 B). 
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Figure 15: Levels of GSH and MDA in diabetic animals. 
Levels of (A) GSH. (B) MDA. One-way ANOVA test, followed by Bonferroni post-hoc 
test for selected groups are used. Results represent mean ± SEM, (n= 6-12), and **: p < 
0.01 
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4.2.6. CBC Results 
     At the given treatment doses and exposure durations, CBC parameters including 
WBC counts and platelet counts were well preserved and no significant effects were 
detected (Figure 16 A & B). Similarly, no significant effects were observed regarding 
hemoglobin levels, RBC counts and hematocrit percentage (Figure 17 A - C). 
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Figure 16: WBC and platelet counts in diabetic animals. 
(A) WBC counts. (B) Platelet counts. One-way ANOVA test, and Bonferroni post-hoc 
test for selected groups are used. Results represent mean ± SEM, (n= 7-10) 
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Figure 17: Hemoglobin, hematocrit and RBC counts in diabetic animals. 
(A) Hemoglobin levels. (B) RBC counts. (C) Hematocrit percentage. One-way ANOVA 
test, and Bonferroni post-hoc test for selected groups are used. Results represent mean ± 
SEM, (n= 7-10) 
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4.2.7. Biochemistry Parameters 
     Lead exposure resulted in significant effects on renal and hepatic functions. In 
comparison to the control group, treatment with high doses of lead acetate i.e. 50 and 
100 mg/ kg caused a statistically significant increase in urea levels (Figure 18 A) and at 
the same time a significant reduction in creatinine levels (Figure 18 B). ALT levels 
were significantly low in all the groups that were exposed to lead acetate (Figure 19 A). 
As for ALP, treatment with increasing doses of lead acetate caused a gradual and 
significant decrease in its levels in the three treatment groups (Figure 19 B). On the 
other hand, lead exposure did not have any significant effect on AST (Figure 19 C). 
Likewise, differences in the levels of CRP, ALB, and total proteins were statistically 
insignificant (Figure 20 A - C).  
 
 
 
 
  
80 
  
 
 
Figure 18: Urea levels and creatinine levels in diabetic animals. 
(A) Urea levels. (B) Creatinine levels. One-way ANOVA test, followed by Bonferroni 
post-hoc test for selected groups are used. Results represent mean ± SEM, (n= 7-14), 
and *: p < 0.05 and **: p < 0.01 
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Figure 19: Levels of ALT and ALP in diabetic animals. 
Levels of (A) ALT. (B) ALP. (C) AST. One-way ANOVA test, followed by Bonferroni 
post-hoc test for selected groups are used. Results represent mean ± SEM, (n= 7-13), 
and *: p < 0.05, and ***: p < 0.001 
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Figure 20: Levels of CRP, ALB and total proteins in diabetic animals. 
Levels of (A) CRP. (B) ALB. (C) Total proteins. One-way ANOVA test, followed by 
Bonferroni post-hoc test for selected groups are used. Results represent mean ± SEM, 
(n= 7-14) 
83 
  
4.3. Discussion  
     In this model, we investigated the effects of lead on the thyroid glands in STZ-
induced diabetic rats. Lead exposure resulted in significant effects on the pituitary-
thyroid pathway, leading to an increase in TSH levels and reductions in T4 and T3 
levels. Our results demonstrated that lead exposure made the animals emaciated. 
Moreover, when the effect of lead on other systems was studied, our results showed a 
depletion of GSH stores and deleterious effects on renal parameters.  
     Our data showed that the rats lost weight during the first week of DM induction. 
This could be attributed to the toxic effects of STZ and the development of DM. 
However, over time, these animals recovered and regained some weight. In comparison, 
normal non-diabetic animals usually gain a significant amount of weight over time. 
However, our data showed that these diabetic rats maintained nearly the same weight 
throughout the six weeks post DM induction. The lack of normal increase in weight in 
these diabetic animals is most probably due to STZ exposure. A previous study showed 
that in comparison to a control group, weight was not affected 12 weeks post-injection 
with 60 mg/ kg of STZ [247]. However, in another study it was shown that six weeks 
after the administration of 50 mg/ kg of STZ to Wistar rats, there was a significant 
amount of weight loss in the STZ-induced diabetic animals in comparison to the control 
group [248].  
     Although the diabetic control rats maintained their weight during the five days of 
treatment, lead acetate treated groups lost significant amounts of weight. This was most 
significant for the group that was treated with 100 mg/ kg of lead acetate as these 
animals lost around 28% of their initial weight during the treatment period. A previous 
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study showed a similar effect of weight loss when animals were treated with 100 µL of 
20 mg/ kg of lead acetate i.p. for 5 days [249].  
     There was a very positive relationship in a dose-response manner between the 
administered doses of lead acetate and the measured BLL in plasma. The exposure to 
25, 50, and 100 mg/ kg of lead acetate resulted in BLL of 1228, 1498, and 2330 ppb, 
respectively. Using the conversion factor: 1 µg/ dL = 10 ppb [199, 200], the measured 
BLL in ppb in the three treatment groups equals 123, 150, and 233 µg/ dL, respectively. 
In clinical settings, such BLL of more than 100 µg/ dL are considered very high and 
would most probably result in severe lead poisoning [250].  
     In this study, we have demonstrated that lead exposure caused an elevation in TSH 
levels, which was statistically significant in the group that was treated with the highest 
dose i.e. 100 mg/ kg of lead acetate. Determination of TSH levels in clinical settings is 
the first step for the diagnosis of thyroid disorders since it is considered to be a more 
precise marker for identifying thyroid malfunctioning than the thyroid hormones 
themselves [251]. Any abnormalities in TSH levels are followed by measuring T4 and 
T3 levels, which in our study were found to be significantly reduced in these diabetic 
animals. Apparently, lead exposure decreased T4 and T3 levels, and this in turn led to a 
positive feedback effect on the anterior pituitary gland increasing TSH secretion. The 
combination of high TSH and low T4 and T3 levels in our study are highly suggestive 
of a clinical hypothyroid state.   
     Both Type I and Type II Diabetes Mellitus are considered to be risk factors for 
developing thyroid disorders [252]. A longitudinal clinical trial has shown that among 
58 patients with Type I DM who were followed up for 18 years, 18 subjects developed 
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hypothyroidism [253]. So is hypothyroidism in our study caused by DM or lead 
exposure? It has been previously demonstrated that injecting rats with 100 mg/ kg of 
STZ could cause a reduction in T4 and T3 levels 12 weeks later. However, the 
administration of smaller doses of 40, 60, and 80 mg/ kg of STZ did not affect T4 and 
T3 levels [247]. Accordingly, the observed reduction in T4 and T3 levels in our study is 
most probably a direct result of lead exposure. Although the animals in our study had 
DM for only 6 weeks, which is relatively a short duration of time, the contribution of 
DM cannot be completely ruled out.  
     Our data show a clear effect of lead exposure on GSH levels (a marker of oxidative 
stress), which were significantly reduced. This can be explained by the fact that GSH 
protects our bodies from reactive oxygen species (ROS) through its sulfhydryl (SH) 
group, to which many reactive species and heavy metals e.g. lead can bind. This would 
eventually lead to a depletion of GSH stores and cause the various systemic toxicities of 
lead exposure such as hepatic and renal damage [254]. On the other hand, MDA, which 
is a „reliable marker‟ and the „most mutagenic product‟ of lipid peroxidation [255], was 
not affected in our study. However, in another study of a longer duration of exposure 
(six weeks), the treated Wistar rats with either 10 or 40 mg/ kg of lead acetate by 
gavage had significantly high MDA levels [256].  
     Our results show that lead exposure had a direct toxic effect on renal functions 
leading to an increase in urea levels. Urea is an end-product of protein degradation and 
is eventually filtered by the kidneys [257]. As such, our data are consistent with a 
recently published study which showed that treatment of mice with 40 mg/ kg of lead 
acetate for 10 days resulted in an increase in urea levels [258]. Along with creatinine 
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levels, urea is a commonly tested marker for renal functions [259]. On the other hand, 
the vast majority of creatinine comes from skeletal muscles and the heart [260]. Since 
creatinine levels are „roughly proportional to muscle mass‟ [259], the most probable 
cause for the significantly low creatinine levels in these diabetic animals in our study is 
emaciation as the animals lost significant amounts of their weight and muscle bulk. In 
another study, when non-diabetic mice were exposed to 40 mg/ kg of lead acetate over 
10 days, this treatment resulted in an elevation in their blood creatinine levels [258].    
     In this study, short-term treatment of diabetic animals with various doses of lead 
acetate over five days caused significant reductions in two biochemical markers i.e. 
ALT and ALP. In contrast to our findings, a previous study showed that lead exposure 
caused liver damage and resulted in elevations in ALT and ALP levels in non-diabetic 
Wistar rats that were exposed to 50 mg/ L of lead acetate in drinking water over 40 days 
[261]. However, in these animals, there were no significant effects on weight. Hence, 
the main cause for the low ALT and ALP levels in our study could probably be due to 
weight loss. It has been previously shown that the intake of low calorie diet over 8 
weeks resulted in significant weight loss, determined as body-mass index (BMI), and 
induced a statistically significant reduction in ALT levels in men [262].  Another study 
showed that among a population of 862 people, the group with normal weight had a 
higher ALT level than the underweight group, and the overweight people had higher 
ALT levels than the group with normal weight [263]. In addition, elevated ALT levels 
have already been associated with metabolic syndrome, central obesity and insulin 
resistance [159].  
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4.4. Conclusion  
     Lead exposure in diabetic animals resulted in several deleterious effects e.g. the rats 
became emaciated. The pituitary-thyroid pathway was significantly affected; as TSH 
levels were elevated and T4 and T3 levels were reduced. In addition, there was a 
significant consumption of GSH stores and impairments in renal and hepatic functions, 
in response to lead exposure.    
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Chapter 5: Hormonal Thyroid Model 
 
5.1. Background  
5.1.1. Regulation of Thyroid Glands 
     The physiological regulation and the hormonal functions of the thyroid gland are 
controlled by higher centers, namely, the hypothalamus and the anterior pituitary gland. 
TRH from the hypothalamus stimulates the anterior pituitary to release TSH, which, in 
turn, induces the thyroid glands to secrete T3 and T4. Iodothyronine deiodinases type 1 
and type 2 will then convert T4 to the more active form i.e. 3,5,3'-triiodothyronine (T3) 
[264]. Despite its extensive use for various purposes, the administration of TRH was 
usually limited to a total duration of less than two weeks in most previous studies since 
its repeated use led to a diminished response i.e. repeated administration of TRH failed 
to sustain TSH concentrations at high levels [265-267]. In addition, it has been shown 
previously that  the maximum response to TRH could be achieved on the fifth day of 
treatment [266]. 
     Somatostatin inhibits the release of TSH [268-270], T4 and T3 [271]. In animal 
models, a single dose of 1 µg of somatostatin injected either intravenously (i.v.) to 
pregnant rats or as i.p. injections to pups caused a reduction in serum TSH levels [272]. 
In comparison to somatostatin, the half-life of its synthetic analogue, octreotide (OCT), 
is 80 times longer and it is also much more potent than somatostatin (16). That is the 
reason why we selected this hormone to induce hypothyroidism in our project. 
Administration of 50 µg of OCT subcutaneously (s.c.) to healthy volunteers inhibited 
TSH release for at least 3 hours (16). In addition, OCT showed an ability to decrease the 
blood supply and vascularity of induced goiters in animal studies [273]. However, in a 
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randomized human study, the administration of 400 µg of OCT as a daily s.c. infusion 
to 7 patients with type I diabetes mellitus for a year resulted in only mild and transient 
hypothyroidism [274].  
 
5.1.2. Induction of Hypothyroidism  
     Various agents have been used for the induction of hypothyroidism in experimental 
animal studies. Some of these that are most commonly used are the antithyroid 
treatment modalities such as propylthiouracil (PTU) [275], methimazole [276] and 
radiation [277]. Additional methods are the use of  iodine [278], lithium [279] and 
hemi-thyroid electrocauterisation [280]. In clinical medicine, hypothyroidism is a 
common complication that is often seen after the administration of anti-thyroid drugs 
[281] and the irradiation of thyroid glands [282]. In addition, both deficiency states and 
excessive amounts of iodine can result in hypothyroidism [278]. On the other hand, 
treatment of bipolar disorders with lithium can result in subclinical hypothyroidism 
[283]. Although it commonly causes hypothyroidism, lithium administration in clinical 
settings has been reported to also induce hyperthyroidism [284]. 
     The use of these agents has been shown to result in several adverse health effects. 
For instance, PTU-induced hypothyroidism in rats caused glucose intolerance since the 
islets‟ cells are probably under the control of T3 and T4 [285]. PTU also causes brain 
changes e.g. tau hyperphosphorylation and an elevation in the levels of 
proinflammatory cytokines, which represent some of the early features of Alzheimer's 
disease [275]. In addition, the administration of 0.05% PTU in drinking water to rats 
over 6 weeks caused an increase in urea, creatinine, homocysteine and MDA levels, in 
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comparison to the control group [286]. Maternal PTU-induced hypothyroidism during 
pregnancy in rats also resulted in a significant reduction in neonatal acetylcholinesterase 
levels, which is one of the most important enzymes in the brain [287]. Similar effects 
have been also seen in clinical practice as maternal treatment with antithyroid 
medications can result in hypothyroidism in their offspring [281]. As such, monitoring 
of maternal free T4 levels is of crucial importance [281].   
     The use of radioactive iodine  in male Fisher rats caused a reduction in the weight 
and volume of thyroid glands as well as several histopathological changes [288]. The 
thyroid glands showed signs of inflammatory reactions, necrotic follicles, and thickened 
blood vessels [288]. In another study, the adverse effects of exposure to iodine were not 
limited to the exposed female rats, but also reached their offspring [289]. Histological 
examination of the thyroid glands of the pups showed hyperplasia and hyperthrophy of 
calcitonin-positive cells, which might predispose these animals to develop endocrine 
diseases in the future [289]. The administration of lithium to experimental rats caused 
oxidative damage, leading to an increase in SOD and MDA levels and a reduction in 
GSH levels [279]. There was also an increase in the osmotic fragility of RBCs, which 
might impair the stability of their membranes [279].  
 
5.1.3. Induction of Hyperthyroidism  
     In comparison, hyperthyroidism in animal studies is often induced by using L-
thyroxine (T4) [290] and triiodothyronine (T3) [291], whereas, in clinical cases, it can 
be the result of exposure to excessive doses of  iodine and amiodarone [292]. The use of 
L-thyroxine in experimental studies has undoubtedly explained and confirmed many 
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hyperthyroid symptoms including cognitive and memory impairments [293]. However, 
this model has its own problems. When rats were treated with 500 mg/ kg, L-thyroxine 
s.c. for a total duration of 12 days, the levels of AST, ALT, LDH, and MDA increased, 
whereas, SOD, CAT, and GSH levels decreased [294]. In addition, treatment of rats 
with 0.3 mg/ kg L-thyroxine i.p. for 3 weeks resulted in an increase in zinc, selenium 
and calcium levels [290]. The induction of hyperthyroidism in rats by using 12.5 µg/ 
100 g body weight of T3 for 10 days resulted in increased apoptosis in the hepatic 
tissues [291].  
     In this project, our aim was to develop an experimental thyroid model through the 
use of TRH to induce hyperthyroidism and OCT to induce hypothyroidism. Our study 
protocol was based on administering these hormones for five days since TRH was 
shown to have its maximum effect on TSH on day five [266].  
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5.2. Results  
5.2.1. Weight Monitoring 
     As was expected in normal animals, the rats in the control group gained weight over 
the five days of treatment with DW. For the other two groups that were treated with 
TRH and OCT, there was statistically no significant weight change (Figure 21).   
 
 
Figure 21: Weight change in hormonal thyroid model. 
The change in weight over the five days of treatment, comparing the initial weight on 
day 1 versus final weight on day 5 within each group. Two-way ANOVA test is used. 
Results represent mean ± SEM, (n= 10-14), and **: p < 0.01 
 
5.2.2. Thyroid Function Tests 
     Treatment of the animals with TRH for five days resulted in an increase in TSH 
levels (Figure 22 A). However, OCT treatment did not have any significant effect on 
TSH levels. On the other hand, the levels of both thyroid hormones, T3 and T4, 
remained statistically insignificant (Figure 22 B & C).    
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Figure 22: Thyroid function tests in hormonal thyroid model. 
Levels of (A) TSH. (B) T4. (C) T3. One-way ANOVA test, followed by Bonferroni 
post-hoc test for selected groups are used. Results represent mean ± SEM, (n= 5-9), and 
**: p < 0.01 
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5.2.3.  GSH Results  
     The treatment protocol did not result in any significant effects on GSH levels in the 
various treatment groups as shown in (Figure 23).   
 
 
Figure 23: GSH levels in hormonal thyroid model.  
One-way ANOVA test, followed by Bonferroni post-hoc test for selected groups are 
used. Results represent mean ± SEM, (n= 8-10) 
 
5.2.4. CBC Results 
     Neither one of the two treatment modalities i.e. TRH or OCT, had any statistically 
significant effect on CBC parameters, which included WBC counts, platelet counts, 
hemoglobin levels, hematocrit percentage and RBC counts (Figures 24 and 25). 
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Figure 24: WBC and platelet counts in hormonal thyroid model. 
(A) WBC counts. (B) Platelet counts. One-way ANOVA test, and Bonferroni post-hoc 
test for selected groups are used. Results represent mean ± SEM, (n= 8-10) 
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Figure 25: Hemoglobin, hematocrit and RBC counts in hormonal thyroid model. 
(A) Hemoglobin levels (B) Hematocrit percentage. (C) RBC counts. One-way ANOVA 
test, and Bonferroni post-hoc test for selected groups are used. Results represent mean ± 
SEM, (n= 5-12) 
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5.2.5. Biochemistry Parameters 
     Treatment of these animals with TRH for five days resulted in an increase in LDH 
levels, in comparison to the control group (Figure 26). However, none of the other eight 
biochemistry parameters that were investigated in these rats was statistically affected by 
exposure to either TRH or OCT (Figures 27 and 28). These parameters included AST, 
ALT, ALP, total bilirubin, albumin, total proteins, urea, and creatinine.  
 
 
Figure 26: LDH levels in hormonal thyroid model.  
One-way ANOVA test, followed by Bonferroni post-hoc test for selected groups are 
used. Results represent mean ± SEM, (n= 7-13), and *: p < 0.05 
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Figure 27: Levels of AST, ALT, ALP and total bilirubin in hormonal thyroid model. 
Levels of (A) AST. (B) ALT. (C) ALP. (D) Total Bilirubin. One-way ANOVA test, followed by 
Bonferroni post-hoc test for selected groups are used. Results represent mean ± SEM, (n= 6-10) 
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Figure 28: Levels of ALB, proteins, urea and creatinine in hormonal thyroid model. 
Levels of (A) ALB. (B) Total Proteins. (C) Urea. (D) Creatinine. One-way ANOVA 
test, followed by Bonferroni post-hoc test for selected groups are used. Results 
represent mean ± SEM, (n= 8-10) 
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5.3. Discussion 
     In this study, we tried to develop an experimental thyroid model using hormones in 
order to mimic the natural physiological process. Although T4 and T3 levels remained 
within normal range, TRH was effective in causing an increase in TSH levels, without 
having other major side effects. However, the use of OCT was not effective at the dose 
and treatment duration that we applied.    
     Animals in the control group gained some weight over time; however, neither TRH 
nor OCT caused any significant changes in weight over the five days of treatment. In a 
previous study, it was concluded that „TRH stimulated resting metabolic rate, but 
inhibited food intake so that the rate of weight gain was reduced in obese (fa/fa) Zucker 
rats‟ [295]. Another study showed that the treatment of female rats with oral TRH for 
30 days resulted in a reduction in their weight [296]. Similarly, it was found out that 
injecting high-fat fed SD rats with 40 µg/ kg octreotide, s.c., twice per day over a total 
duration of 8 days resulted also in weight loss, in comparison to an obese control group 
[297]. In addition, data from clinical studies also support the role of OCT in causing 
weight loss in obese subjects [298, 299]. The difference in the effect on weight between 
our study and these previous studies is probably related to the use of different doses and 
treatment durations.  
     Our data show that TRH treatment resulted in a statistically significant increase in 
TSH levels, although both of T4 and T3 were not increased. In this respect, it has been 
shown previously that the administration of TRH orally over 30 days caused an increase 
in T3 levels in female rats [296]. Similarly, injecting cattle with a single dose of 1 µg/ 
kg of TRH i.v. resulted in a slight elevation in T4 and T3 levels [300]. The use of OCT 
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in our study did not have any effect on TSH, T4 and T3 levels, although OCT is known 
to suppress TSH levels and has been used successfully in several medical cases for the 
treatment of pituitary adenomas [301, 302].  
     For systemic parameters, our experiments resulted in only an increase in LDH levels 
in response to TRH treatment, whereas, none of the other biochemical parameters was 
affected. The lack of systemic effects after TRH administration was also demonstrated 
in a previous study, where, treatment of cattle with 1 µg/ kg of TRH, i.v. did not have 
any effect on several biochemical parameters that were tested including ALT, creatine 
phosphokinase (CPK), gamma-glutamyl transpeptidase (GGT), LDH, cholesterol, 
albumin and blood minerals including calcium, phosphorus, and magnesium [300]. In 
addition, the administration of TRH in our experiments had no significant effect on 
hemoglobin concentrations, hematocrit, or RBC counts. Likewise, WBC and PLT 
counts were not affected.  
     Similarly, the use of OCT in our study did not affect the various systemic parameters 
that we tested. These included CBC, oxidative stress markers, and biochemical 
parameters. In a previous clinical study, 43 patients with acute pancreatitis were divided 
into a control group and an OCT treatment group, where the patients in this group 
received 0.5 µg/ kg/ hr OCT as continuous i.v. infusion. No significant difference was 
noticed between the two groups in regard with fasting blood glucose, hemoglobin, 
hematocrit, white blood cell count, calcium, LDH, AST, albumin, and urea levels 
neither at the time of presentation nor two days later [303]. As such, the use of OCT 
over short durations of time of few days did not cause any major systemic 
complications.  
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5.4. Conclusion  
     In this model, we established an increase in TSH levels in response to TRH 
administration, although it did not cause a corresponding increase in T4 and T3 levels. 
Apart from an increase in LDH levels, the animals tolerated this protocol very well as 
all the other parameters were within normal range. Taken together, these findings 
indicate that the administration of exogenous TRH is apparently safe and does not cause 
major adverse health effects. 
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Chapter 6: General Conclusions and Future Directions 
 
6.1. Conclusion  
     In the first model, which involved the use of healthy animals, we have demonstrated 
that lead exposure resulted in several multisystemic effects. The most important effect 
was subclinical hypothyroidism i.e. high TSH and normal T4 and T3 levels. The other 
effects are related to hepatic and renal damage, which are clearly seen as several 
abnormal parameters in their respective panels. Since thyroid hormones were not 
affected at this stage, these abnormalities are probably a direct result of lead toxicity 
through oxidative damage and inflammation.  
     In the diabetic model, treatment with lead acetate caused clearer effects on the 
pituitary-thyroid axis. Here, the hormonal changes were consistent with a clinical 
hypothyroid state as the animals had high TSH and low T4 and T3 levels. Lead 
exposure in STZ-induced diabetic rats caused oxidative damage in the form of having a 
reduced level of the essential antioxidant, GSH. Lead exposure also resulted in renal 
damage leading to an elevation in urea levels. On the other hand, creatinine levels were 
reduced; perhaps due to muscle wastage.  
     The hormonal thyroid model resulted in a partial effect. TRH was effective in 
causing an increase in TSH levels, without having any major effects on other organ 
systems, apart from increasing LDH levels. However, OCT could not affect the 
pituitary-thyroid pathway since the various involved hormones (TSH, T4 and T3) 
remained within normal ranges.  
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     In summary, short-term lead exposure in healthy and diabetic animal models 
affected the functions of the anterior pituitary and thyroid glands, caused oxidative 
stress, liver and kidneys toxicity and induced systemic inflammation. 
 
6.2. Future Directions   
     In this research, we were able to demonstrate clear effects of lead exposure on the 
pituitary and thyroid glands, in both healthy and diabetic rats. As such, it is of 
paramount importance to uncover the mechanism of action of lead on these vital organs 
i.e. in addition to descriptive studies, mechanistic toxicity studies that target the 
molecular details on the pituitary-thyroid pathway need to be carried out. Furthermore, 
since lead exposure only caused subclinical hypothyroidism in the healthy animals, 
additional studies over longer periods of time are needed; since such exposures might 
eventually proceed to full-blown hypothyroidism. Since the group of 1 mg/ kg lead 
acetate did not produce significant effects in the non-diabetic animals, this group can be 
eliminated in future studies. In this project, STZ was used to induce DM, whereas, for 
future studies, other diabetic models e.g. NOD or BB models need to be considered and 
utilized. Here, the data from the healthy and diabetic animals were analyzed separately 
i.e. within each model. It would also be a good idea to compare the two models to each 
other.  
     There were several limitations in the newly developed experimental thyroid model. 
The first one is the total lack of effects of OCT on TSH, T4 and T3 levels. The second 
limitation is our inability to induce an increase in T4 and T3 levels in response to TRH 
administration, despite having a significant increase in TSH levels. In order to 
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overcome these issues and to optimize the hormonal responses, we recommend carrying 
out additional experiments where different doses of TRH and OCT are used. These 
experiments need to be tried over different time-points i.e. shorter and longer durations 
until the optimal response is achieved. 
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